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Small Molecules to Control Porcine Reproductive and Respiratory Syndrome Virus 
Infection 
Chang Huang, Ph.D. 
University of Connecticut, 2020 
Porcine reproductive and respiratory syndrome (PRRS) is an economically significant 
panzootic affecting the swine industry worldwide. The genetic and antigenic variation of existing 
PRRS virus (PRRSV) strains and constantly evolving characteristic of PRRSV present great 
challenges for the development of effective vaccines and treatments against heterologous 
PRRSV strains. In this study, we investigated novel approaches to combatting the PRRS 
panzootic.  
The scavenger receptor CD163 has been reported as indispensable for PRRSV infection. 
Thus, in our study, porcine CD163 receptor was regarded as a valuable target for inhibition of 
PRRSV infection. Two antiviral approaches were investigated 1) downregulating CD163 
expression in porcine alveolar macrophages (PAMs), and 2) blocking the protein-protein 
interactions (PPIs) between PRRSV and porcine CD163.  
In the first approach, we validated that the interleukin 10 (IL-10) stimulated Janus kinase 
(JAK)-signal transducer and activator of transcription 3 (STAT3) signaling also upregulated 
CD163 expression in pig cells as it does in humans. We tested 3 STAT3 inhibitors validated 
previously and identified cryptotanshinone (Cpt), a natural compound extracted from the herb 
Salvia miltiorrhiza (Danshen), as an efficient inhibitor of IL-10 stimulated and basal level of 
CD163 expression in PAMs. We further found Cpt was able to suppress infection of PAMs by 
type I and type II PRRSV.
Chang Huang – University of Connecticut, 2020 
In the second approach, we established specific bimolecular fluorescence 
complementation (BiFC) assays to study PPIs between PRRSV glycoprotein GP2a or GP4 and 
the fifth scavenger receptor cysteine-rich domain (SRCR5) of porcine CD163. Using one BiFC 
assay, we tested 74 chemical compounds predicted to bind with porcine CD163-SRCR5 domain 
obtained by a structure-based virtual screening program. We identified one synthetic compound 
(4-Fluoro-2-methyl-N-[3-(3-morpholin-4-ylsulfonylanilino)quinoxalin-2-
yl]benzenesulfonamide, C25H24FN5O5S2), designated herein as B7, efficiently blocked the PPI 
between PRRSV GP2a/GP4 and porcine CD163-SRCR5 domain. We found compound B7 was 
able to substantially inhibit infection of PAMs by type I and type II PRRSV in vitro. We further 
characterized some B7 analogues in vitro and identified some small molecules with similar 
antiviral efficacy as B7. We also proposed that 3-(morpholinosulfonyl)anilino moiety of B7 or 
the 3-(piperidinylsulfonyl)anilino moiety of a B7 analogue could be pharmacophore important 
for the anti-PRRSV activity.
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Chapter 1. Literature Review 
1.1 PRRSV relevance 
Porcine reproductive and respiratory syndrome (PRRS) was first reported as an 
unrecognized and catastrophic disease in the U.S. in 1987 (Keffaber, 1990) and then in Germany 
in 1990 (Wensvoort et al., 1992). The disease is characterized by reproductive disorder of sows 
and respiratory syndrome of piglets and growing pigs (Zimmerman et al., 2012). Clinical signs 
of reproductive disorder are decline in milk yield/agalactia in sows, late-term abortion and early 
or delayed farrowing that contain dead and mummified fetuses, stillborn pigs, and weak-born 
piglets. The respiratory syndrome is recognized by coughing, pneumonia, fever, and anorexia 
(Goyal, 1993). The PRRS etiology was first resolved by researchers at the Central Veterinary 
Institute (Lelystad, the Netherlands) and designated as Lelystad virus after fulfillment of Koch’s 
postulates (Terpstra et al., 1991). Shortly thereafter, the causative virus responsible for the 
outbreak in the U.S. was isolated and designated as American Type Culture Collection VR-2332 
(ATCC VR-2332) (Benfield et al., 1992). Later characterization of PRRS virus (PRRSV) strains 
originated in Europe (type I) and North America (type II) demonstrated striking genetical 
divergence. In the following years the disease has become an epizootic in most swine-producing 
regions. An “atypical” or “acute” variant first appeared in Iowa, United States in the mid 1990s 
(Mengeling et al., 1998). In 2001, an abrupt appearance of a highly virulent PRRSV strain 
named MN184 occurred in Minnesota, USA (Han et al., 2006). In 2006, the emergence of the 
notable highly-pathogenic PRRSV (HP-PRRSV) in China affected over 2 million pigs and 
caused about 400,000 fatalities (Tian et al., 2007). Control of PRRS is problematic and during 
the past 2 decades, PRRS has become one of the most economically significant diseases 
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affecting swine industry, costing $664 Million to the United States annually (Holtkamp et al., 
2013).  
1.2 PRRS prevention and control 
PRRS prevention includes any practice to preclude either the introduction of PRRSV into 
naive herds or the introduction of new PRRSV strains into positive herds. Pig repopulation and 
semen for artificial insemination constitute the major source of PRRSV to a herd (Le Potier et 
al., 1997). Semen should be routinely tested using a PCR-based assay prior to its used in 
artificial insemination. All replacement breeding stocks are required to originate from a large 
unit tested PRRSV negative. In addition, the replacement stock should be under quarantine for at 
least 30 days and then tested for PRRSV load before introduced to the breeding herd 
(Zimmerman, 2006). All the movement of inputs and outputs from the farms, e.g. feed delivery, 
manure removal, personnel activity, entry or other animals, and entry of air/water, hold the 
potential to carry virus into a herd (Zimmerman et al., 2019). Biosecurity efforts can be taken to 
prevent PRRSV importation. These precautionary actions include transport vehicle sanitation 
and drying, personnel behaviors in accordance with entry protocols (e.g. shower-facilities and 
Danish entry system), and insect control programs (e.g. screens, habitat management, and 
insecticides) (Zimmerman et al., 2019). For dense-populated pig barns, air filtration may be used 
to prevent PRRSV, which is also shown to reduce the introduction of other airborne pathogens, 
such as Mycoplasma hyopneumoniae (Otake et al., 2010; Spronk et al., 2010).  
Efforts to treat PRRS efficiently fail. Most practices of PRRS control are aiming to limit 
the adverse effects caused by PRRSV in various production stages. During an acute outbreak, 
antibiotics, e.g. Tetracycline, Penicillin, and Trimethoprim-sulfonamide, are administered to 
ameliorate secondary infection caused by bacterial pathogens (Aarestrup et al., 2008). Consistent 
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acclimatization of the incoming replacement gilts constitutes an important part of any efficient 
PRRSV control program. The objective of these efforts is to confer protective immunity to the 
gilts and lower the incidence of PRR outbreak after the introduction of these gilts to the breeding 
herd. The initial step of gilt acclimatization is to confine the gilts in designated facilities for gilt 
development unit as many production systems perform (Dee et al., 1997). During the 4 to 6-
month period before they enter the breeding herd, replacement gilts develop protective immunity 
activated by MLVs, or by farm-specific wild-type virus in the form of live virus inoculation 
(LVI). LVI typically involves inoculating gilts with serum collected from acutely infected pigs 
since the serum contains farm-specific PRRSV strains (Zimmerman et al., 2019). Note that the 
method is inherently risky primarily because the safety and efficacy of this procedure has not 
been well characterized like commercial MLVs. Therefore, it is important to measure the viral 
load in the serum and administer a standardized dose, as well as validate the absence of some 
hazardous agents in the serum prior to administration. In addition, whole herd vaccination has 
been applied to immunize subpopulations of naïve pigs (Dee et al., 1996). Application of whole 
herd vaccination has been reported to reduce the time taken before the yield of a breeding herd 
producing PRRSV-negative weaned piglets, and to improve biological and financial performance 
of the chronically infected herd (Linhares et al., 2014). 
Apart from gilt acclimation, PRRSV eradication from a herd is also essential for an 
efficient PRRS control program. Chances that PRRSV is eliminated spontaneously from a herd 
are remote, creating problems for consistent PRRS control. Several methods have been used to 
eliminate PRRSV from a herd, including total depopulation/repopulation, partial 
depopulation/repopulation, test and removal, and herd closure (Corzo et al., 2010). Applications 
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of these methods to achieve successful PRRSV elimination are case-by-case, depending on 
immune status of a herd, unit size, cost, and stages of production, etc.  
Total herd depopulation and repopulation is very efficient but costly. This method is 
justifiably prioritized on occasions when the farrow-to finish herds are inflicted with PRRSV 
infection, and when elimination of concurrent infection caused by other pathogens is required, 
both of which collaborate to make elimination of the virus via other methods inefficient 
(Zimmerman, 2006). Partial depopulation, on the other hand, is usually used to eliminate PRRSV 
from a growing herd which is largely PRRSV negative. When used in a large unit (>500 sows), 
additional methods (e.g. herd enclosure or test-and-removal) are recommended to eradicate 
PRRSV from the breeding herd prior to attempting elimination in the pig flow (Zimmerman, 
2006).  
During operation of herd closure, all the pigs previously exposed to PRRSV are enclosed 
without any introduction of replacement animals to the herd, prior to complete elimination of the 
virus from the herd. This practice is based on the fact that though PRRSV exists persistently in 
the immunized herd, it will eventually be eradicated by the immune system of the pig 
(Torremorell and Conroy, 2003). Since an immune population will undergo persistent infection 
before PRRSV extinction, a long period of enclosure is required. As a rule of thumb, a 6-month 
period is recommended while the period can be variable depending on the status of the farm and 
pig flow. After the elimination of the virus from the enclosed herd, replacement pigs originated 
from a negative herd are then introduced following attrition or scheduled culling of the 
previously infected pigs (Zimmerman et al., 2019).  
Candidate herds for test-and removal include herds with an estimated prevalence under 
25%, more than 12 months since the last clinical observation of PRRS, and segregated 
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production (Zimmerman, 2006). Test-and-removal is recommended for herds where there is no 
indication of PRRSV recirculation in the herd, and where the presence of pigs with persistent 
infection still poses potential threat to the PRRS control program. PRRSV elimination through 
test-and removal involves testing blood samples of the breeding herd, identifying PRRSV 
positive pigs by testing antibody and virus, and culling infected pigs from the herd (Dee et al., 
2004; Dee and Philips, 1998).   
1.3 PRRS virion and genome structure 
The causative agent of PRRS is PRRSV which belongs to the family Arteriviridae, order 
Nidovirales. Other viral species of the family Arteriviridae include lactate dehydrogenase-
elevating virus (LDV), equine arteritis virus (EAV), and simian hemorrhagic fever virus (SHFV) 
(Dunowska et al., 2012; King et al., 2011; Plagemann and Moennig, 1992). PRRSV is an 
enveloped, single-stranded, and positive sense RNA virus. The virion has a genome of 14.9 kb to 
15.5 kb packed by a proteinaceous nucleocapsid surrounded by a lipid membrane, the envelope 
where five or six structural proteins are embedded (Figure 1.1B). The virion has a spherical to 
oval shape with a size ranging from about 50 to 70 nm in diameter (Spilman et al., 2009).  
The PRRSV genome encodes a 5’-untranslated region (5’UTR) of 217-222 nucleotides in 
type I genotype and 188-191 nucleotides in type II genotype (King et al., 2011; Yun and Lee, 
2013). The genome contains 10 known open reading frames (ORFs). The downstream of  5’UTR 
has the large overlapping replicase ORFs which are situated in the first three fourths of the 
PRRSV genome (Kappes and Faaberg, 2015). The large ORFs consist of ORF1a and ORF1b 
which share a single translational start site but conclude translation at two different ribosomal 
frame shift sites (Fang et al., 2012) (Figure 1.1.A). The ORF1a and ORF1b regions encode four 
large nonstructural polyproteins, pp1a, pp1a-nsp2N, pp1a-nsp2TF, and pp1ab which are 
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subsequently processed into at least 14 nonstructural proteins. These nonstructural proteins have 
a wide range of functions including potential interferon (IFN) antagonism, forming replication 
and transcription complex (RTC), membrane modification, and RNA-dependent RNA 
polymerase (Lunney et al., 2016). ORFs 2a, 2b, and 3 to 7 only make up approximately one 
fourth of the viral genome at the 3’ end, and they encode the viral structural proteins, 
specifically, glycoprotein 2a (GP2a), GP3, GP4, GP5, protein E, the matrix protein (M), and the 
nucleocapsid protein (N),  respectively (Wu et al., 2005) (Figure 1.1.B). Protein M and protein E 
are non-glycosylated while GP2a, GP3, GP4, and GP5 are N glycosylated envelope proteins 
(Dea et al., 2000). GP5 is the most abundant glycoprotein on the viral envelope, hence its name 
the major envelope glycoprotein. By contrast, the GP2a, GP3, and GP4 proteins only constitute a 
small proportion of the envelope glycoproteins, and are therefore classified as the minor 
envelope glycoproteins (Das et al., 2010).   
1.4 PRRSV taxonomy and classification 
The European (EU) and North American (NA) isolates belong to 2 genetically distinct 
genotypes, and were later officially designated as Type I (PRRSV-1, EU genotype) and Type II 
(PRRSV-2, NA genotype) PRRSV. Lelystad and VR-2332 strains, both discovered in 1991, are 
the prototype wildtype parental strains of PRRSV-1 and PRRSV-2, respectively. Nucleotide 
sequence analysis indicates the 2 genotypes vary by approximately 44%. Furthermore, 
phylogenetic analyses largely based on ORF5 demonstrate remarkable divergence between the 2 
PRRSV genotypes. Comparative analyses of the nucleotide sequence show the sequence 
variation is up to 30% among representative PRRSV-1 strains and exceeds 21% among PRRSV-
2 strains (Zimmerman et al., 2019). The extraordinarily diverse genetic composition may be 
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primarily due to the lack of PRRSV RNA-dependent RNA polymerase proofreading and  
tremendous viral recombination (Keffaber, 1989).  
Though these 2 PRRSV genotypes distinct substantially, molecular clock analysis shows 
PRRSV-1 and PRRSV-2 can be originated from a common ancestor that existed at least 100 
years ago, but evolved independently in geographically or ecologically distinct environments 
since then, in a yet-to-be-identified host (Forsberg, 2005). PRRSV-1 has further been divided 
into 4 subtypes. PRRSV-1 subtype 1 to which Lelystad virus belongs, is prevalent in the whole 
Europe, while PRRSV-1 subtype 2, 3, and 4 are primarily present in Eastern Europe (Stadejek et 
al., 2013). Phylogenetic analysis based on ORF5 of PRRSV-1 subtype 1 strains, identified 12 
diverse linages while 9 distinct lineages have been defined by ORF5 phylogeny of PRRSV-2 
(Hasita et al., 2010; Shi et al., 2010). Seven lineages of PRRSV-2 are mostly present in North 
America while the other 2 lineages are only prevalent in East Asia. The PRRSV-2 outbreaks in 
Asia seem to occur primarily due to introductions of the North American lineages followed by 
local evolution (Hu et al., 2009; Zhao et al., 2015). The genomes of existing PRRSV field 
isolates are also constantly evolving with a higher rate (order of 10-2/site/year) than the estimated 
rate (10-3 to 10-5/site/year) for other RNA viruses (Hanada et al., 2005). Considerable genetic 
variations among PRRSV strains consequently leads to differences in virulence and 
pathogenesis. Some strains only cause subclinical infection to farms while more pathogenic 
strains, like Lena strain in Type I and HP-PRRSV in Type II in China, afflict swine herd with 
high mortality (Karniychuk et al., 2010; Tian et al., 2007).  
1.5 Viral infectivity  
PRRSV causes persistent infection to carrier animals. A susceptible and infected pig 
usually undergoes 3 distinct stages before PRRSV is cleared from the body: acute infection, 
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persistence, and extinction, each of which demonstrates unique immunology, virology, and 
clinical disease. The acute infection occurs when the pig is infected with PRRSV at the initial 
stage and the virions replicate primarily in the dendritic cells and macrophages in the upper 
respiratory tract and the lungs, respectively. Then viremia occurs 6-12h post infection. Viremia 
may last for several weeks before virus is no longer detectable in blood and lungs. Then the 
infection proceeds to the second stage of persistent infection during which the infected pig is 
majorly asymptomatic. At this phase, viral replication primarily occurs in lymphoid organs, 
including tonsil and lymph nodes but not spleen (Allende et al., 2000; Rowland et al., 2003; 
Wills et al., 1997a). During this process, the continuously replicating virus may be shed through 
oral and nasal secretions (Wills et al., 1997a), urine (Wills et al., 1997b), semen (Swenson et al., 
1994), and occasionally feces (Christianson et al., 1993). Virus shedding from persistently 
infected pigs is one of the most unsettling respects of PRRSV infection adding to the difficulties 
in efficient control of viral infection in the field. Subsequently, the virus presence progressively 
decline until the virions are eliminated from the host. The eventual disappearance of virus marks 
the final stage of infection, the extinction. The duration that PRRSV replication can be 
maintained may be up to 250 days, and this figure differs from pig to pig (Wills et al., 2003).    
Swine is the only known natural host of PRRSV. In vivo, the virus has a very narrow 
tropism, only causing reproductive infection to cells of monocyte macrophage system. The fully 
differentiated porcine alveolar macrophages (PAMs) are considered the primary target for 
PRRSV infection (Duan et al., 1997). Additionally, dendritic cells were proved to be permissive 
to PRRSV infection (Loving et al., 2007). In vitro, the African green monkey kidney cell line 
MA-104 and its derivate cell lines, MARC-145 and CL-2621, are reported to support PRRSV 
infection and replication. In addition, some recombinant cell lines, such as CHO-K1, BHK-21 
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and porcine kidney cell-15 (PK-15), are generated from originally non-permissive cells and 
turned susceptible to PRRSV infection upon expression of recombinant receptor proteins (Shi et 
al., 2015a). 
The receptor-mediated PRRSV entry has been well documented with various receptors 
reported involved in this process (Delputte et al., 2005; Shi et al., 2015a; Van Breedam et al., 
2010). Heparan sulphate was identified as one PRRSV attachment factor that concentrate virions 
on the cell surface, but it is not sufficient to render cells permissive to PRRSV since many non-
permissive cells possess heparan sulphate (Delputte et al., 2005). After early attachment of 
virions to heparan sulphate, another attachment receptor, sialoadhesin, was reported to mediate 
more stable interaction with PRRSV. Then the virus internalizes the host cells via a process of 
clathrin-mediated endocytosis (Delputte et al., 2005; Vanderheijden et al., 2003).  However, 
sialoadhesin is not essential for PRRSV infection either. In an in vitro study, PRRSV was able to 
enter naturally non-permissive PK-15 cells transfected with sialoadhesin, but not capable of 
reproductive replication in the transfected cells (Prather et al., 2013). After internalization, the 
viral genome is then released into early endosomes (pH = 6.0 to 6.5) following endosome 
acidification and viral colonization with scavenger receptor CD163 (Van Gorp et al., 2009). 
CD163 plays a pivotal role in viral uncoating and genome release of PRRSV, and is postulated 
the only known indispensable receptor for PRRSV infection so far. Evidence supporting its 
indispensability for PRRSV infection includes an in vitro study reporting that overexpression of 
CD163 alone in BHK-21 (an originally PRRSV non-permissive cell) confers the cells 
susceptibility to PRRSV infection (Guo et al., 2014). In addition, in vivo experiments revealed 
that CD163 knock-out pigs are resistant to PRRSV infection (Burkard et al., 2017; Whitworth et 
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al., 2015). Therefore, CD163 was identified as a key factor in the initiation of PRRSV infection 
and may be targeted to control PRRSV infection.  
1.6 Scavenger receptor CD163 in PRRSV infection and its regulation 
1.6.1 CD163 in PRRSV infection 
CD163 is a type I transmembrane glycoprotein which belongs to the scavenger receptor 
cysteine- rich (SRCR) family and is mainly expressed on cells of the monocyte/macrophage 
lineage (Van Breedam et al., 2010). Extracellularly, it is made up of nine SRCR domains with 
SRCR domain 6 (SRCR6) and SRCR7 separated by a 35-amino-acid proline-serine-threonine 
(PST)-rich region and a signal peptide following SRCR9 (Van Breedam et al., 2010; Van Gorp 
et al., 2010) (Figure 1.2). In a previous study, a set of chimeric mutants of CD163 were 
generated by swapping SRCR domains with corresponding regions of CD163-L1, a paralogue of 
human CD163 that does not promote PRRSV infection (Van Gorp et al., 2010). Then PRRSV-
non-permissive HEK293T cells were transfected with different chimeric mutants and the 
potential of the different mutants to sustain PRRSV infection was evaluated. The SRCR5 of 
CD163 was identified to have a leading role in PRRSV infection. Another study identified 
glycoproteins of PRRSV that were responsible for mediating interaction with CD163 (Das et al., 
2010). CD163 receptor as well as each of the glycoproteins of PRRSV were sub-cloned into 
expression vectors and these constructs were transfected into BHK-21 cells. The interactions of 
the proteins with each other in the transfected cells were examined using coimmunoprecipitation. 
The results suggested that PRRSV glycoproteins GP2a and GP4 served as the viral attachment 




1.6.2 Regulation of CD163 expression 
The regulatory mechanism for CD163 expression has been extensively studied in humans 
due to its anti-inflammatory roles. CD163 is exclusively expressed in monocytes/macrophages 
(Buechler et al., 2000). Anti-inflammatory cytokine Interleukin 6 (IL-6) and IL-10 substantially 
stimulate, whereas proinflammatory cytokines interferon-γ (IFN-γ) and tumor necrosis factor-α 
(TNF-α) strongly inhibit CD163 transcription and protein expression (Buechler et al., 2000; 
Sulahian et al., 2000). Among these cytokines, IL-10 is responsible for the regulatory T cell-
induced expression of CD163 in monocytes/macrophages, and the upregulation of CD163 
induced by the activation of Toll like receptor (TLR) 2 or TLR5 agonists (Tiemessen et al., 2007; 
Weaver et al., 2007), or upon the stimulation with lipopolysaccharide (LPS) or hemoglobin-
haptoglobin (HbHp) complex (Boyle et al., 2009; Sulahian et al., 2004). IFN-γ inhibits CD163 
expression through regulating IL-10. IFN-γ and IL-10 mutually suppress the expression of each 
other in monocytes (Donnelly et al., 1995), and the inhibition of CD163 expression by IFN-γ can 
be rescued by exposure to IL-10 in peripheral blood mononuclear cells (PBMCs) (Weaver et al., 
2007). Additionally, IL-10 inhibits the expression of TNF-α (another CD163 inhibitor) induced 
by IFN-γ or LPS in both PBMCs and alveolar macrophages (Chomarat et al., 1993; Donnelly et 
al., 1995). Therefore, IL-10 plays a central part in modulating CD163 transcription in humans. 
In human macrophages, IL-10 stimulation activates Janus Kinase (JAK), which 
specifically activates signal transducer and activator of transcription 3 (STAT3) (Carey et al., 
2012; Murray, 2007). The activated STAT3 dimerizes and translocates into the cell nucleus for 
transcriptional regulation (Carey et al., 2012; Murray, 2007). Inhibition of STAT3 significantly 
downregulates the transcription of both IL-10 and CD163 (Hasita et al., 2010; Nakamura et al., 
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2015), identifying the IL-10- stimulated signaling pathway as a valuable target for inhibiting 
CD163 expression. 
The regulation of CD163 expression in pigs has yet to be elucidated, although porcine 
CD163 shares conserved amino acid sequence and functional domains to its counterparts in 
human, primate, and rodent (Perez et al., 2008), and is abundantly expressed in pig macrophages 
(Sánchez et al., 1999). The regulatory sequence that mediates CD163 gene expression in pigs is 
still unknown. However, similar to humans, IL-10 stimulates CD163 expression in pig 
monocytes at the protein level (Perez et al., 2008; Sánchez et al., 1999). Furthermore, the IL-10- 
induced increase of CD163 protein expression leads to greater susceptibility of pig macrophages 
to PRRSV infection (Patton et al., 2009). These data support that the IL-10- stimulated signaling 
pathway is a potential target for the prevention PRRSV infection by inhibiting CD163 
expression. However, whether porcine CD163 transcription is regulated by IL- 10-stimulated 
signaling pathway similarly to humans is unclear. In addition, whether we can minimize PRRSV 
susceptibility of porcine alveolar macrophages (PAMs), the primary PRRSV target in pigs by 
modulating the signaling pathway has not been explored. 
1.7 Viral replication cycle 
As described in section 1.5 Viral Infectivity, PRRSV internalizes the host cells via a 
process of clathrin-mediated endocytosis and has its genome released to the host cell cytoplasm 
following endosome acidification and viral colonization with scavenger receptor CD163. CD163 
mediates uncoating and release of the viral genome, which is followed by initiation of translation 
and transcription processes required for the formation of new virions. The ORF1a/b on the first 
three-fourths of the genome yield replicase polyproteins pp1a, pp1a-nsp2N, pp1a-nsp2TF, and 
pp1ab through two programmed ribosomal frame shift sites (Fang et al., 2012) (Figure 1.4). 
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These polyproteins are cleaved by viral internal proteinases papain-like cysteine proteinases 
(PLP) 1α, PLP1β and PLP2, and the main serine proteinase to generate at least 14 nonstructural 
proteins (Snijder et al., 2013). These nonstructural proteins are then assembled into a replication 
and transcription complex (RTC) following rearrangement of host membranes (Yuan et al., 
2004). First, the RTC engages in the synthesis of minus-strand full-length genome and a set of 
nested subgenomic RNAs (sgRNAs) (Pasternak et al., 2004) (Figure 1.4). Subsequently, minus-
strand genome and sgRNAs serve as templates to synthesize plus-strand genome and sgRNAs. 
The set of nested sgRNAs (+) yield corresponding structural proteins as indicated in Figure 1.4 
(Kappes and Faaberg, 2015). The generated genome RNA is assembled with these structural 
proteins in a highly ordered process, which include formation of heterodimer composed of GP5 
and M, synthesis of a hetero-trimer that facilitates viral entry consisting of minor glycoproteins 
GP2a, GP3 and GP4 (Mardassi et al., 1996; Wissink et al., 2005), and enclosure of genome RNA 
by a core capsid formed by homo-oligomerization of N protein (Wootton and Yoo, 2003; Yoo et 
al., 2003). After the assembly, the virion becomes enveloped by budding from smooth 
intracellular membranes (Wissink et al., 2005). Ultimately, the new virions accumulate in 
intracellular vesicle, which are subsequently delivered to the plasma membrane before shed from 
the cells via an exocytosis process (Wissink et al., 2005).   
1.8 Innate and adaptive immunity against PRRSV 
1.8.1 Type I interferon response   
The most effective innate anti-viral immune response is the production of type I 
interferons (IFNs) IFN-α and IFN-β by infected cells, of which the autocrine and paracrine 
actions instigate the comprehensive host immune response to protect the host cells against viral 
infection in the early stages. Macrophages and dendritic cells are the most potent cells of 
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producing type I IFN, notably a subset of dendritic cells, namely, plasmacytoid dendritic cells 
(pDCs). Signaling pathways for type I IFN production will be reviewed below (Figure 1.5). 
Toll-like receptors (TLRs) have been well documented in their functions of mediating 
type I IFN production. Among them, endosome-based TLRs 3, 7, 8, and 9 have been reported to 
contribute extensively to the control of virus infection (Baccala et al., 2007). TLR3 is present in 
intracellular endosomes of most cell types and it recognizes pathogen-associated molecule 
patterns (PAMPs) poly(I:C) and double stranded RNA (dsRNA) (Karikó et al., 2004; Okahira et 
al., 2005). TLR7 in human is abundantly expressed in pDCs while TLR8 is primarily present in 
monocytes and they both recognize single-stranded RNA (ssRNA) as PAMPs (Gantier and 
Williams, 2007). TLR9 senses unmethylated CpG DNA in the genome in DNA viruses (Vollmer 
et al., 2004). Binding with the PAMPs leads to the dimerization of corresponding receptors and 
recruitment of  Toll/IL-1R domain-containing adaptor inducing IFN-β (TRIF) by TLR3 
(Vercammen et al., 2008) or MyD88 by TLRs 7/8/9 (O'Neill and Bowie, 2007). The stimulation 
of TRIF or MyD88 leads to the assembly of signaling complexes and initiation of signaling 
cascades resulting in the phosphorylation and activation of Activating Protein 1 (AP-1), NF-κB, 
interferon regulatory factor 3 (IRF3), and IRF7 (Honda et al., 2006; Vercammen et al., 2008). 
After the activation, these transcription factors translocate to the cell nucleus and bind with co-
transcription factors CREB-binding protein (CBP) to form an IFN enhanceosome to induce the 
transcription of IFN-α and IFN-β. 
Another signaling mediating type I IFN production is Retinoic acid inducible gene I and 
melanoma differentiation associated gene-5 (RIG-I/MDA5) pathway (Figure 1.5). RIG-I and 
MDA-5 are both DExD/H box RNA helicases with ATPase activity, which possess two N-
terminal caspase recruitment domains (CARDs). RIG-I recognizes short dsRNA ligands 
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(<300 bp) with 5′-triphosphate caps (Hornung et al., 2006) whereas MDA5 recognizes long 
double stranded genomic RNA and replication intermediates (>1,000 bp) with no end specificity 
(Pichlmair et al., 2006). The PAMPs binding induces conformational changes and oligomeric 
CARD assemblies between RIG-I and MDA5 which nucleate the polymer formation of the 
signaling adaptor IFN-β promoter stimulator-1 (IPS-1), another CARD-containing protein on the 
mitochondrial and peroxisomal membranes (Berke and Modis, 2012). Subsequently, the IPS-1 
polymers stimulate signaling pathways that result in the activation of IRF3, IRF7, and NF-κB 
through different adaptors and kinases (Hou et al., 2011). The IPS-1 also cascades its signal to 
MAP kinase which is involved in the activation of AP-1 (Liu et al., 2014). The activated IRF3, 
IRF7, NF-κB, and AP-1 are translocated into the nucleus, and recruit co-transcription factors, 
such as CBP to form IFN enhanceosome to induce the transcription of IFN-α and IFN-β (Honda 
et al., 2006). Additionally, another mediator, LGP2 has similar helicase and C-terminal domain 
as RIG-I and MDA5 but lacks the tandem CARDs (Barral et al., 2009). LGP2 downregulates 
signaling by RIG-I attributed to its ability of competitively recognizing the same PAMPs as RIG-
1 (Rothenfusser et al., 2005; Yoneyama et al., 2005). In contrast, LGP2 stimulates MDA5 
signaling (Yoneyama et al., 2005). Thus, LGP2 could control the balance between RIG-I and 
MDA5 responses during viral infection.  
Once IFN-α and IFN-β are synthesized through either TLR signaling or RIG-I/MDA5 
pathway, they are secreted extracellularly and bind to IFN receptors on itself (autocrine) or 
neighboring cells (paracrine). The binding initiates JAK-STAT signaling pathway (Figure 1.5) 
that upregulates over 300 IFN-stimulated genes (ISGs) which later result in the establishment of 
antiviral state in uninfected cells. The binding to receptor induces conformational changes in the 
receptors which activate Jak1 and Tyk2 pre-associated on the receptors. The activated Jak1 and 
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Tyk2 phosphorylate the signal transducers and activators of STAT1 and STAT2 followed by the 
STAT1-STAT2 dimerization in the cytosol. The heterodimer recruits IRF9 and form the 
transcription factor complex namely Interferon-stimulated gene factor 3 (ISGF3). ISGF3 then 
translocates into the nucleus and binds to a consensus DNA sequence of TTTCNNTTTC known 
as IFN-I-stimulated response element (ISRE) leading to the activation of transcription of over 
300 ISGs (Ivashkiv and Donlin, 2014). However, a relatively small number of these genes confer 
antiviral state to uninfected cells by cytoskeletal remodeling for apoptosis, regulation of post-
transcriptional events, and post-translational modifications. Many other ISGs serve as pattern-
recognition receptors (PRRs) to recognize viral molecules or as transcription factors that 
facilitate IFN production and preventing virus infection (Sadler and Williams, 2008). Among all 
the ISGs, 2', 5'-oligoadenylate synthetase 1 (OAS1), RIG-I, RNA activated Protein Kinase 
(PKR), myxovirus resistance (MxA), and ISG15 are the most extensively studied, and function 
as antiviral effectors (Sun et al., 2012).  
1.8.2 Innate immune responses to PRRSV infection 
The innate immunity is the first line of host defense against viral infections. It includes 
physical barriers, such as skin and mucous membrane; chemical barrier, like pH, lipids and 
enzymes; and immune cells, such as dendritic cells, macrophages, neutrophils, mast cells, and 
natural killer (NK) cells. The most effective innate anti-viral immune response is type I IFN 
production by the virus-infected cells. PRRSV has been reported to modulate host innate 
immunity, and in turn adaptive immunity leading to chronic persistent infection as previous 
studies have shown that virus can be detectable from secondary lymphoid organs such as tonsils 
and lymph nodes months after initial infection (Allende et al., 2000; Loving et al., 2015; Lunney 
et al., 2016). Unlike other swine respiratory viruses that are capable of inducing considerable 
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IFN-α response, e.g. swine influenza virus and porcine respiratory coronavirus, PRRSV 
stimulates moderate to negligible IFN-α production in the respiratory tract. Suppression of Type 
I IFNs in pigs infected with HP-PRRSV (Xiao et al., 2010) or European genotype of PRRSV 
(Ait-Ali et al., 2011) has been validated using microarray analysis, indicating that PRRSV is able 
to manipulate IFN signaling pathways during infection.  
TLR3, TLR7, and TLR8 have been identified important for type I IFNs production and 
thus innate antiviral activity against PRRSV infection. Porcine bone marrow hematopoietic cell-
derived immature dendritic cells (imDCs) were exposed to PRRSV in a previous study which 
showed such exposure inhibited TLR3, TLR7, and TLR8 expression at 6 h post infection (hpi) in 
the imDCs, and that TLR3 and TLR8 levels returned to basal levels by 24 hpi whereas TLR7 
expression decreased continuously through 24 h of infection (Chaung et al., 2010), suggesting 
that PRRSV may suppress type I IFNs production through TLR signaling. In contrast, TLR3 
level in PRRSV-infected cells was significantly downregulated by poly(I:C) or LPS in another 
study, which facilitated PRRSV replication (Miller et al., 2009).  
A number of PRRSV Nsp’s have been reported to suppress type I IFNs production by 
targeting IFN enhanceosome through IRF-mediated RIG-I/MDA5 pathways. Nsp 1 possesses the 
most potent ability to suppress the IFN-β activity partly due to the degradation of CBP in the 
nucleus. Consequently, the enhanceosome formation is disrupted and then the IFN gene 
expression is blocked (Kim et al., 2010). Nsp1β is able to suppress type I IFNs by  inhibiting 
phosphorylation and nuclear translocation of IRF3 (Kim et al., 2010). Nsp2 is known to 
downregulate type I IFNs production due to its poliovirus 3C-like cysteine protease (CP) and 
deconjugation activities associated with inhibiting IRF3 phosphorylation and nuclear 
translocation, and with mediating ISGs and NF-κB signaling, respectively (Li et al., 2010). 
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Nsp11 blocks the phosphorylation of both IκB and IRF3 which leads to the suppression of the 
nuclear translocation of NF-κB and IRF3 and to the consequent inhibition of IFN production. 
The inhibition of NF-κB and IRF3 is likely caused by the degradation of the upstream IPS-1 by 
Nsp11 (Nedialkova et al., 2009). Another pathway involving a protective response of the host to 
viruses and modulated by PRRSV is NF-κB signaling. The PRRSV N protein appears to induce 
NF-κB activation in a dose-dependent manner and the activation may be linked to the N protein 
nuclear localization and N-N homo-dimerization (Sun et al., 2012). In contrast, Nsp1α was found 
to be able to inhibit the NF-κB activation by inhibiting the phosphorylation of the upstream IκBα 
and then blocking the NF-κB nuclear translocation (Song et al., 2010). Nsp2 has also been 
reported to suppress the NF-κB activation though the mechanism is obscure (Li et al., 2010).  
PRRSV not only inhibit type I IFN production but also deter the host cell from 
establishing antiviral state by suppressing the IFN-inducible signaling pathways, primarily JAK-
STAT signaling (Patel et al., 2010). PRRSV inhibits JAK-STAT signaling by blocking ISGF3 
translocation into nucleus (Patel et al., 2010). PRRSV also induces STAT2 degradation and 
shortens STAT2 half-life significantly by nsp11 interaction with STAT2 to inhibit JAK-STAT 
signaling (Yang et al., 2019). It was found that PRRSV significantly inhibits ISGs expression 
both in MARC145 cells and PAMs as indicated by the decreased ISG15, ISG56 transcription and 
CCL2, MX1, OAS2 mRNA in the PRRSV-infected cells, respectively (Patel et al., 2010).   
Additionally, PRRSV infection may undermine activation of the host innate system 
through dysregulation of NK cells. NK cells are the innate lymphocyte subset involved in the 
nonspecific elimination of any virus-infected cells from the host. Following infection with 
PRRSV, NK cell frequency decreases but returns to normal levels a few weeks after PRRSV 
infection (Dwivedi et al., 2011b). However, independent of the fluctuation in NK cell number by 
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PRRSV infection, suppression of NK cell cytotoxic activity is observed as early as two days post 
initial infection and continues for three to four weeks (Dwivedi et al., 2011a; Renukaradhya et 
al., 2010). The modulation of these NK cell properties during PRRSV infection is coordinated by 
multiple cytokines, such as IFNα, IFNβ, IL-12, and IL-15, and the debilitated basal NK cell 
cytotoxic activity by viral infection is mediated through the STAT1 pathway (Lee et al., 2000).   
1.8.3 Adaptive immune responses to PRRSV infection 
Though PRRSV evades the host innate immune response to avoid rapid clearance from 
the host, the impaired host innate immunity against viral infection may cascade its effect to 
adaptive immune response of the host during PRRSV infection, contributing to PRRSV 
persistence in the host. One key feature of the dysregulated adaptive immune responses to 
PRRSV infection is delayed secretion of neutralizing antibodies (NAbs). NAbs are not usually 
detected prior to 4 weeks after initial challenge (Yoo et al., 2010). Though PRRSV infection 
stimulates an antibody response by as early as 7 to 9 days post infection, no evidence shows that 
early antibodies can provide sterilizing immunity against PRRSV challenge to the pig (Lopez et 
al., 2007; Lopez and Osorio, 2004). These earliest and non-neutralizing antibodies are directed 
against the 15 kDa N protein, the 19 kDa M protein and then the 26 kDa GP5 envelope 
glycoprotein chronologically (Loemba et al., 1996). Interestingly, epitope mapping identifies a 
range of non-neutralizing epitopes located in Nsp2, suggesting that this major nonstructural 
protein serves an immunodominant role (de Lima et al., 2006; Oleksiewicz et al., 2001). Reports 
in regard to the role of NAbs against PRRSV infection have been confounding and sometimes 
paradoxical. For examples, some studies indicate that viremia and viral replication can persist 
with circulating NAbs, and in other cases, viremia vanishes from the host before NAbs appears 
(Mateu and Diaz, 2008; Nelson et al., 1994; Vezina et al., 1996). PRRSV persists in lymphoid 
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tissues, such as tonsils and lymph nodes in presence of high-titers of circulating homologous 
PRRSV NAbs (Murtaugh et al., 2002). These together can be interpreted as the idea that PRRSV 
NAbs are not directly correlated with PRRSV clearance. In contrast, serum transfer experiments 
show that high-titered NAbs can transfer passive protection and prevent transplacental PRRSV 
infection of piglets and confer sterilizing immunity against PRRSV infection on both the sow 
and her offspring in utero (Lopez et al., 2007).  
Glycan shielding effects of N-linked glycosylation in glycoproteins have been postulated 
to be a primary mechanism for delayed NAbs (Ansari et al., 2006). It has also been reported that 
an upstream decoy epitope lures the immune response away from more protective neutralizing 
epitope in GP5 (Ostrowski et al., 2002). Another factor that may contribute to delayed secretion 
of NAbs is a known phenomenon as antibody-dependent enhancement in which infection and 
replication of PRRSV are enhanced in the presence of specific antibody in vivo and in vitro  
(Cancel-Tirado et al., 2004). In addition, PRRSV dysregulates innate immunity and causes 
abnormal B cell repertoire development, particularly lymphopenia and thymic atrophy, which 
may hinder virus clearance by NAbs (Butler et al., 2014). 
As described above, PRRSV infection is able to dysregulate IFN-α response. The 
autocrine IFN-α may induce pDCs to express co-stimulatory molecules that facilitate the 
differentiation of naïve T cells into IFN-γ-producing cells (Honda et al., 2003). Therefore, 
PRRSV can also affect adaptive immune response of the host by the cascading effects of 
dysregulated innate immunity by PRRSV challenge. The lack of efficient stimulation of IFN-α 
secretion in host cells by PRRSV exposure would be expected to have a major impact on the 
cell-mediated immunity of the host, for IFN-α stimulates IFN-γ gene expression, and thus control 
the dominant pathway that promotes T cell-mediated IFN-γ responses and robust antiviral 
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immune defenses (Levy et al., 2003). Apart from phenotypic changes of T lymphocytes by 
PRRSV infection, this viral challenge can also induce a reduction in circulating lymphocyte early 
after infection in young pigs, constituting another potential mechanism that PRRSV 
compromises host’s adaptive immune responses against the virus (Sinkora et al., 2014).   
1.9 Antiviral strategies against PRRSV infection 
Vaccination for food animals is a common approach to combat infectious disease. 
Currently, commercial modified live vaccines (MLV)  has been developed against both PRRSV-
1 and PRRSV-2 strains, and licensed in various regions depending on the circulating strains (Du 
et al., 2017). However, unlike MLVs against EAV that provide effective protection to the horses, 
efforts to control PRRSV infection using MLVs fail primarily because MLVs based on a single 
PRRSV strain provide poor cross-protection against heterologous strains (Zhou et al., 2012). 
Various potential antiviral strategies other than conventional MLVs have emerged in recent 
years. These strategies suppressed PRRSV infection at different steps of the PRRSV replication 
cycle, or target some antiviral signaling to boost host immunity against PRRSV  (Zhou et al., 
2012).  
The two PRRSV receptors, sialoadhesin and CD163 mediate virion internalization to the 
host cells and viral uncoating, respectively. Soluble form of sialoadhesin and CD163 from 
transduced 3D4/21 or PK-15 cells are able to capture PRRSV virion and inhibit PRRSV 
infection of PAMs in vitro, and the anti-PRRSV activity is even more striking when the PRRSV-
infected PAMs are co-treated with secretory sialoadhesin and CD163 (Chen et al., 2014). A 
mouse (Mus musculus) monoclonal anti-idiotypic antibody (Mab2-5G2) hampers interaction of 




RNA interference techniques, either small interfering RNAs (siRNAs) or short-hairpin 
RNAs (shRNAs), targeting nonstructural protein (Nsp) 1α (Shi et al., 2015b) and Nsp9 (Xie et 
al., 2014),  and the genes encoding the nucleoprotein (Yang et al., 2014), and ORF1 region of 
PRRSV (Li et al., 2007) have been reported to block PRRSV infection in vitro. Nanobodies 
targeting Nsp4 and Nsp9 have been screened for anti-PRRSV efficacy, and these nanobodies 
were shown to inhibit PRRSV replication by interfering PRRSV replication and transcription 
complex (RTC) assembly (Liu et al., 2016; Liu et al., 2015).  
Some crude traditional Chinese medicine (TCM) extracts, including Tanshinone IIA from 
root of Salvia miltiorrhiza (Sun et al., 2014), Epigallocatechin gallate (Zhao et al., 2014) and tea 
seed  saponins (Li et al., 2015) from tea, and  flavaspidic acid AB from Dryopteris crassirhizoma 
(Yang et al., 2013), have been shown to inhibit PRRSV replication in vitro. However, all of these 
studies only tested anti-PRRSV activity of crude extracts or agents but not specific agents in 
vitro and did not characterize efficacy in vivo. Additionally, some of them seem to inhibit 
replication of various viruses and the underlying mechanisms for their antiviral ability are still 
elusive. Therefore, TCM extracts are far from being ready for practical use in anti-PRRSV 
therapy. 
As for agents stimulating antiviral signaling against PRRSV, several Toll-like receptor 
(TLR) ligands, including poly (I:C), SZU-101, and CL907, which are recognized by TLR3, 
TLR7, and TLR7/8, respectively, are shown to inhibit PRRSV replication in vitro by activating 
the innate immune response (Du et al., 2016; Hu et al., 2016; Miller et al., 2009; Sang et al., 
2008; Zhang et al., 2013). In addition, recombinant porcine IFN-β and IFN-γ are able to inhibit 
PRRSV replication in vitro, showing some vaccine adjuvant potential (Bautista and Molitor, 
1999; Overend et al., 2007). Pigs that were inoculated with recombinant adenovirus for IFN-α 
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expression one day prior to PRRSV challenge show delayed viremia and antibody response and 
alleviated lung lesion (Brockmeier et al., 2009). In an in vivo study, recombinant pig IL-12 was 
reported to boost humoral and cell-mediated anti-PRRS immunity in swine when used as an 
adjuvant with an inactivated vaccine (Wee et al., 2001).   
1.10 Rational and hypotheses of this research 
Either MLVs and inactivated vaccines provide poor cross-protection against heterologous 
PRRSV strains. In addition, despite tremendous efforts in investigating alternative methods as 
described above, efficient control of PRRS is still lacking. Though the indispensability of CD163 
receptor for PRRSV infection in pigs has been well documented, few studies have targeted 
porcine CD163 using small molecules to inhibit PRRSV infection either in vitro or in vivo. In 
this research, 2 hypotheses were raised: 1) We propose that the downregulated porcine CD163 
expression by small molecules will protect PAMs against heterologous PRRSV strains in vitro. 
2) We further propose that small molecules that disrupt the CD163-PRRSV interaction will 
provide PAMs with cross-protection against heterologous PRRSV strains in vitro. These 2 
hypotheses were addressed in the following 2 research projects, respectively.  
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Figure 1. 1: Genome and virion structures of PRRSV. (A) The two ORFs on the 5’ end of the 
genome encode four large nonstructural polyproteins, pp1a, pp1a-nsp2N, pp1a-nsp2TF, and pp1ab 
that are subsequently cleaved into at least 16 nonstructural proteins. The remaining ORFs of the 
genome on the 3’ end encode structural proteins associated with viral envelope and RNA 
packaging. (B) A PRRSV mature virion consists of single stranded genome enclosed in 
nucleocapsid proteins which is further wrapped up in a lipid bilayer envelope with multiple viral 














Figure 1. 2: Schematic structure of scavenger receptor CD163. From N terminus to C terminus, 
the receptor is made up nine SRCR domains with SRCR domain 6 (SRCR6) and SRCR7 separated 
by a 35-amino-acid proline-serine-threonine (PST)-rich region and with SRCR9 followed by a 











Figure 1. 3: A preliminary model of the PRRSV envelope protein complex and its interaction 
with CD163 on the host cell plasma membrane. The pearl-on-a-string structure on the 
extracellular region of the host cell represent the nine SRCR domains making up the extracellular 
scavenger receptor CD163. The two glycoproteins on the PRRSV envelope, namely GP2a and 
GP4, collaborate to mediates PRRSV interaction with the CD163 at the fifth SRCR domain 






Figure 1. 4: PRRSV genome, transcription and translation. PRRSV replication is 
accomplished by a range of genetic and protein regulatory mechanisms. The two ORFs making up 
about three fourth of PRRSV genome encode 4 large polyproteins, namely pp1a, pp1a-nsp2N, 
pp1a-nsp2TF, and pp1ab through two documented programmed ribosomal frame shift sites (●). 
Subsequently, the polyproteins are cleaved into at least 14 nonstructural proteins which are then 
assembled into a replication and transcription complex (RTC). The RTC engaged in the synthesis 
of minus-strand full-length genome and a set of nested subgenomic RNAs (sgRNAs) before they 
serve as template to produce positive-strand genome and sgRNAs which encode glycoproteins on 








Figure 1. 5: Signaling pathways for typeⅠ IFN production and IFN stimulated gene 











2.1. Toll-Like Receptor (TLR) Signaling 
Toll-like receptors (TLRs) have been investigated extensively in the past few years and a 
considerable progress has been made for mammalian TLRs and their functions. TLRs are a family of 
proteins recognizing different pathogen-associated molecule patterns (PAMPs). The key signaling 
domain unique to the TLR system is the toll/interleukin (IL)-1 receptor (TIR) domain located in the 
cytosolic face of each TLR and also in the adapters [26]. Once engaged to TLRs, PAMPs recruit 
different kinases through different adaptors by the TIR domain and thus trigger different signaling 
pathways, leading to the expression of specific genes that are involved in the removal of invading 
viruses. Ten TLRs have so far been identified for humans and 11 TLRs for mice [27]. Of these, TLRs 
3, 7, 8, and 9 are discussed in this review since they contribute the most to the control of virus 
infection [28].  
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Abstract  Porcine reproductive and respiratory syndrome (PRRS), caused by PRRS virus 
(PRRSV) infection, causes enormous financial losses to the global swine industry. Currently 
there are no effective treatments to prevent PRRSV infection in pigs. Here we report that the 
natural compound cryptotanshinone (Cpt) is able to effectively inhibit PRRSV infection by 
heterologous PRRSV strains in porcine alveolar macrophages (PAMs) in vivo, the primary cell 
target of PRRSV infection. Mechanistically, Cpt inhibits the activation of signal transducer and 
activator of transcription 3 (STAT3), and blocks the interleukin 10 (IL-10) stimulated, as well as 
the basal level CD163 expression in PAMs. Cpt- treatment of PAMs is effective when 
administered either before or after PRRSV infection, or with the combined pre- and post-PRRSV 
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infection treatment resulting in significant, dose-dependent inhibition of PRRSV infection. Our 
study identified a new approach to potentially preventing/treating PRRSV infection by using 
natural compounds. 
Keywords  PRRSV, IL-10, STAT3, CD163, Cryptotanshinone, PAM 
2.1 Introduction 
Porcine reproductive and respiratory syndrome (PRRS) leads to an annual loss of $664 
million to the United States pork industry, and is one of the most economically significant 
diseases for swine industry worldwide (Holtkamp et al., 2013). The causative agent of the 
disease is porcine reproductive and respiratory syndrome virus (PRRSV), an enveloped, positive-
sense, single-stranded RNA virus, belonging to the Arterivirus genus within the family 
Arteriviridae and order Nidovirales (Benfield et al., 1992; Cavanagh, 1997). PRRSV is divided 
into two genetically distinct genotypes, type I (European genotype) and type II (North American 
genotype). PRRS leads to severe reproductive disorders in sows and respiratory diseases mostly 
in piglets (Music and Gagnon, 2010). These syndromes are frequently accompanied by 
secondary infections with even more severe clinical manifestations and mortality (Zimmerman et 
al., 1997). However, due to the high genetic, antigenic, and pathogenic heterogeneities among 
various PRRSV strains, vaccines providing cross-strain protection against PRRSV are lacking 
(Meng, 2000; Murtaugh et al., 2010). Alternative approaches to combatting the PRRS panzootic 
are worthy of studying. 
PRRSV has a narrow cell tropism in pigs, preferentially targets and replicates in well- 
differentiated cells of monocyte/macrophage lineage (Duan et al., 1997; Music and Gagnon, 
2010; Rossow, 1998; Teifke et al., 2001; Thanawongnuwech et al., 1997). Productive viral 
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infection occurs principally in porcine alveolar macrophages (PAMs) residing in the lung 
(Murtaugh et al., 2002). In vitro, the African green monkey kidney cell line MA-104 and its 
derivates, MARC-145 and CL-2621, are shown to support PRRSV infection and replication 
among many tested cell lines. CD163, a cell membrane scavenger receptor, is the key receptor 
for PRRSV infection in pigs. Genetic knockout studies revealed that deletion of CD163, but not 
another receptor sialoadhesin, produced PRRSV- resistant pigs (Prather et al., 2013; Whitworth 
et al., 2015). PRRSV directly interacts with CD163 via its minor glycoproteins GP2a and GP4 
(Das et al., 2010), and CD163 is reported to mediate the uncoating and genome release of the 
virions for productive infection after virion internalization (Van Gorp et al., 2008, 2009; 
Vanderheijden et al., 2003). However, cellular mechanisms that regulate pig CD163 expression 
are still obscure. 
In human cells of the monocyte/macrophage lineage, cytokines interleukin 6 (IL-6) and 
IL-10 substantially stimulate CD163 transcription and expression (Buechler et al., 2000; Högger 
et al., 1998; Sulahian et al., 2000). IL-6 or IL-10 stimulation activates Janus kinase (JAK), which 
specifically activates the transcription factor signal transducer and activator of transcription 3 
(STAT3) (Carey et al., 2012; Murray, 2007). Inhibiting STAT3 significantly downregulates the 
transcription of both IL-10 and CD163 (Hasita et al., 2010; Nakamura et al., 2015), identifying 
that IL-10- stimulated signaling pathway as a valuable target to inhibit the expression of CD163. 
However, little is known about the regulation of CD163 expression in pigs, although porcine 
CD163 shares conserved amino acid sequence and functional domains with its human, primate, 
and rodent counterparts (Perez et al., 2008), and is highly expressed in macrophages (Sánchez et 
al., 1999). It was reported that in pig macrophages, IL-10−induced increase of CD163 protein 
expression which leads to a greater susceptibility to PRRSV infection (Patton et al., 2009). These 
 
 45 
data support that the IL-10−stimulated signaling pathway is a potential target for the prevention 
of PRRSV infection. However, whether porcine CD163 is transcriptionally regulated by IL-10 
similarly as in humans is unclear. Also, whether we can minimize PRRSV susceptibility of 
PAMs, the primary PRRSV target in pigs, by modulating the activities of CD163 expression- 
regulating pathways has not been explored. 
Here we report that in primary PAMs, inhibiting IL-10 controls STAT3 activity and 
CD163 expression at the transcriptional and translational levels. We further discovered that 
Cryptotanshinone (Cpt), a selective STAT3 inhibitor and natural compound derived from the 
herb Salvia miltiorrhiza (Danshen) (Chen et al., 2014; Shin et al., 2009), exhibits significant 
inhibitory effect to the infection of PAM cells by type I and type II PRRSV in PAMs. 
2.2 Materials and Methods 
Chemicals, Cells, and Viruses.  STAT3 inhibitors Stattic, 5,15-DPP (Stat3 Inhibitor 
VIII) and Cpt were purchased from Abcam (Cambridge, MA, USA). Porcine IL-10 was from 
R&D Systems (Minneapolis, MN). PAMs were harvested from healthy 4–6-month old castrated 
male Landrace/Yorkshire cross pigs based on a protocol approved by the institutional animal 
care and use committee (IACUC) at the University of Connecticut. Briefly, lungs were removed 
from euthanized pigs during necropsy and transferred on ice to a Class II Biosafety cabinet. A 
bronchoalveolar lavage was then performed by injection of 200 mL warm sterile PBS containing 
200 U/mL penicillin and 200 µg/mL streptomycin through trachea into major bronchi of both 
sides of the lungs. Lungs were massaged and bronchoalveolar lavage fluid was collected. The 
fluid was centrifuged at 400 g for 15 min to collect PAMs. The PAMs were washed twice, 
counted and frozen in 90% fetal bovine serum (FBS) (Rocky Mountain Biologicals, Missoula, 
MT) and 10% dimethyl sulfoxide (DMSO) (Sigma- Aldrich, St. Louis, MO) at -80 ℃ overnight 
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before transferred to liquid nitrogen. PAMs were cultivated in RPMI-1640 (Life Technologies, 
Calsbad, CA) supplemented with 10% FBS (Rocky Mountain Biologicals), 2 mM Glutamax 
(Invitrogen, Carlsbad, CA), 0.1 mM MEM Non-Essential Amino Acids, 1mM sodium pyruvate, 
100 U/mL penicillin and 100 µg/mL streptomycin, and 0.5 µg/mL Amphotericin B 
(ThermoFisher Scientific, Grand Island, NY). Type I PRRSV strain Lelystad (LY), and type II 
PRRSV strains VR- 2332 and SDSU73 used for infection assays were propagated and titrated 
using MARC145 cells as described previously (He et al., 2011; Overend et al., 2007). 
Determination of Cytotoxicity of STAT3 inhibitors.  PAMs (1×107 cells) were seeded 
into a 24-well plate. After overnight incubation, three STAT3 inhibitors were diluted with 
complete medium to different concentrations (0 - 20 µM), and 500 µl of each concentration was 
added to PAMs. Cells were incubated for 24 h, then 50 µl of the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) labeling reagent (In Vitro Toxicology Assay Kit, MTT 
based, Sigma- Aldrich) were added to each well for 4 h, followed by 500 µl of the solubilization 
solution into each well to fully dissolve the formazan crystal by overnight incubation based on 
manufacture’s instruction. The absorbance of samples was measured using a spectrophotometry 
microplate reader at 600 nm. PAMs treated with DMSO were served as controls. 
Quantitative Reverse Transcription – PCR (qRT-PCR).  Total RNAs were isolated 
from PAMs using RNeasy Mini Kit (Qiagen, Germantown, MD) according to the manufacturer’s 
instruction. RNA concentrations were measured using a Nanodrop spectrophotometer 
(ThermoFisher Scientific). Specific real-time qPCR primers for STAT3, SOCS3, CD163, 
GAPDH, and the ORF7 gene of 3 strains of PRRSV are shown in Table 2.1. qPCR reactions 
were performed with SYBR Green supermix (Bimake, Houston, TX) using the ABI 7500 Fast 
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platform (ThermoFisher Scientific). GAPDH was used as the housekeeping gene for gene 
expression normalization. Data were processed with the software associated with ABI 7500. 
Immunostaining and Western-Blotting (WB).  The treated PAMs were rinsed with 
cold DPBS. The cells were then fixed with 4% para-formaldehyde for 15 min. Following three 
washes by DPBS, the cells were permeabilized with 0.5% TX-100 at room temperature for 5 
min. The cells were blocked in 5% goat serum for 1 h at room temperature before they were 
incubated with PE-conjugated anti-CD163 monoclonal antibody (Invitrogen) diluted 1:10, 
phospho (p)-STAT3 at Tyr705 (1:100, Cell Signaling Technology, Danvers, MA), or with 
PRRSV antibody SDOW17-F (1:500, RTI, LLC, Brookings, SD) at 37 °C for 2 h. The cells were 
then counter-stained with DAPI (Invitrogen) for 5 min and washed. The fluorescence was 
observed with an inverted Nikon fluorescence microscope and a Nikon A1R confocal 
microscope. 
For WB, whole cell proteins were isolated from PAMs at indicated time points. Briefly, 
the cells were rinsed twice with cold PBS. After removing the PBS, cold RIPA buffer 
(ThermoFisher Scientific) supplemented with 1% (v/v) protease and phosphatase inhibitors was 
added to the cells and placed on ice for 5 min. Protein concentrations were determined using 
Pierce BCA Protein Assay Kit (ThermoFisher Scientific). Equal amount of denatured proteins 
from each sample were separated on 10% SDS-PAGE and transferred onto a PVDF membrane. 
The membrane was incubated with 5% skim milk to block nonspecific binding before incubation 
with anti-CD163 antibody (1:750; Abcam, Cambridge, MA), anti-phospho-STAT3 at Tyr705 
(1:1,000), or anti- GAPDH antibody (1:2,000; Cell Signaling Technology) overnight at 4 °C. 
After washing with 1×T-BST, the membrane was incubated with HRP-conjugated secondary 
 
 48 
antibody for 1 h at room temperature, and image developed with ECL Blotting Substrates (Bio-
Rad) and visualized under the ChemiDox XRS Image System (Bio-Rad). 
PRRSV Infection and Viral Titration Assays. For PRRSV infection of PAM cells, PAMs 
were seeded one day prior to infection. Cells were inoculated with one of the 3 strains of PRRSV 
at multiplicity of infection (MOI) of 0.1 for 1 h. After removing the inoculum, the cells were 
washed once with DPBS. The cells were incubated with DMSO or Cpt during the 24 – 48 h pre-
inoculation period or the 21-24 h post-inoculation period. A detectable, rapid PRRSV 
amplification stage in infected PAMs occurs between 12-36 h post inoculation before reaching a 
plateau for titer (Burkard et al., 2017). We chose the 21 h time- point in the middle of the 
dynamic stage to measure the inhibitory effect on viral replication by Cpt. The cell medium 
supernatant was stored at -80 °C until future titration assay. The PRRSV titer in the culture 
supernatant was determined by the inoculation of 10 - fold serially diluted supernatant in 
quadruplicate into MARC-145 cells seeded in 48-well plates. The inoculum was removed from 
cells after 2 h and replaced with 0.5 mL of DMEM supplemented with 2% FBS, 2 mM 
Glutamax, 0.1 mM MEM Non-Essential Amino Acids, and 50 U/mL penicillin and 50 µg/mL 
streptomycin (Invitrogen) to each well. Cells were cultured at 37 °C for 6 days and the wells 
with cytopathic effect were recorded. The titer was calculated using the Reed and Müench 
method (Reed and Muench, 1938) and expressed as median tissue culture infectious dose 
(TCID50)/mL. 
Statistics analysis.  All experiments were performed at least 3 times. Data were analyzed 
by one-way ANOVA with Tukey’s post hoc comparison or by paired t-test. Data were expressed 




IL-10 Stimulates CD163 Transcription and Translation in PAMs. We first tested if 
IL-10 could stimulate CD163 transcription and protein expression in pig cells. Incubation with 
100 ng/mL of porcine IL-10 for 2 h and 24 h stimulated STAT3 activity in primary PAMs, as 
indicated by the increased expression of STAT3 direct target – SOCS3 (Hutchins et al., 2015; 
O’Brown et al., 2015) detected by quantitative reverse transcription – polymerase chain reaction 
(qRT-PCR) (Figure 2.1A). We further noticed that at 24 h, IL-10 treatment significantly 
promoted CD163 gene expression compared with the bovine serum albumin (BSA) control (Ctl) 
(Figure 2.1A). The IL-10 enhanced CD163 protein expression in PAMs was confirmed by 
immunostaining after 24 h stimulation (Figure 2.1B). This can be explained by the IL-10 
stimulated increase of phospho (p)-STAT3 at Tyr705 (Figure 2.1B). Thus, IL-10 stimulates 
CD163 transcription and translation in PAMs. 
Cpt Inhibits IL-10−Induced and Basal Level CD163 Expression in PAMs. We next 
asked if inhibiting STAT3 would block the CD163 expression in pig cells. To target IL-
10/STAT3 pathway, we compared 3 previously described STAT3-specific inhibitors: 5, 15-DPP 
(DPP) (Nakamura et al., 2015; Uehara et al., 2009), Stattic (Schust et al., 2006), and Cpt (Shin et 
al., 2009), which were reported to inhibit STAT3 at concentrations of 5, 20, and 7 µM, 
respectively (Figure 2.2A). The cytotoxicity of these compounds to PAMs was first determined 
by MTT assay. Except for Cpt, obvious cytotoxicity was observed for the other 2 compounds at 
24 h with concentrations at 10 µM (Stattic) or above 10 µM (DPP) (Figure 2.2A). 
We then treated PAMs for 24 h using these compounds with adjusted concentrations (10 
µM DPP, 5 and 7 µM Stattic, 7 and 20 µM Cpt), with or without IL-10 stimulation. Under these 
conditions, we did not observe obvious STAT3 inhibitory effect by DPP or Stattic in PAMs 
 
 50 
(Figure 2.2B). However, we observed significant inhibition of basal level or IL-10 stimulated 
STAT3 activity by 7 and 20 µM Cpt treatment, as measured by the expression of STAT3 target 
SOCS3 (Figure 2.2B). Similarly, the basal level or IL-10 stimulated CD163 expression in PAMs 
was significantly decreased by treatment with 7 and 20 µM Cpt, while DPP or Stattic treatment 
showed little effect (Figure 2.2C). The inhibition of IL-10 stimulated STAT3 activity and CD163 
protein level by Cpt was determined by Western-Blotting (WB) (Figure 2.2D). Also, PAMs co-
treated with IL-10 and Cpt for 24 h exhibited obvious inhibition of IL-10 stimulated CD163 
expression by immunostaining (Figure 2.2E). In addition to the inhibition of IL-10 stimulated 
CD163 expression, we further verified that the basal expression level of CD163 protein in PAMs 
was also inhibited by Cpt- treatment (Figure 2.2F). Therefore, the STAT3 inhibitor Cpt imposes 
significant inhibitory effect to CD163 mRNA and protein expression in primary PAM cells. 
Cpt Pre- or Pre- Plus Post-treatment Inhibits PRRSV infection of PAMs in vitro. We 
then asked if inhibiting CD163 expression by Cpt could block or mitigate PRRSV infection of 
pig cells. To this end, we first treated PAM cells for 48 h with 5 or 10 µM Cpt, followed by 
inoculation of PRRSV VR-2332 strain for 1 h (MOI = 0.1). PAMs were lysed at 21 h post 
inoculation and total RNAs were extracted to evaluate the PRRSV infection of PAMs. qRT-PCR 
revealed that PRRSV infection was significantly inhibited in PAMs with 10 µM Cpt pre-
treatment (p = 0.003), which was consistent with the reduced CD163 expression in treated PAMs 
(Figure 2.3A). The culture media from different treatments were collected at 21 h post 
inoculation. Viral titration experiments were performed and showed that pre-treatment of PAMs 
with 10 µM Cpt significantly reduced the viral titer in the culture medium (p = 0.024) (Figure 




We then questioned if Cpt could inhibit PRRSV infection of PAMs stimulated by IL-10. 
PAMs were pretreated with DMSO, IL-10, Cpt, or IL-10 plus Cpt for 24 h, inoculated with 
PRRSV VR- 2332 strain, and then immunostained for PRRSV at 24 h after. The results of these 
tests further verified that Cpt pretreatment significantly reduced the percentage of PRRSV 
infected PAM cells (Figures 2.3C, 2.3D). As expected, treatment with 100 ng/mL IL-10 
increased the percentage of PRRSV infected PAMs (p = 0.015) (Figures 2.3C, 2.3D). However, 
co-treatment with 10 µM Cpt offset the IL-10 stimulated increase of PRRSV infection of PAMs 
(Figures 2.3C, 2.3D). Thus, Cpt pretreatment can inhibit the PRRSV infection of PAM cells even 
in the presence of IL-10. 
We further tested the effect of pretreatment with Cpt for 24 h plus post-inoculation 
treatment for 21 h after viral inoculation of PAMs (pre- plus post-treatment). PAMs were treated 
accordingly and lysed thereafter with total RNAs extracted to evaluate the PRRSV infection. 
qRT-PCR analysis on lysed PAMs revealed that both 5 and 10 µM Cpt treatments significantly 
inhibited PRRSV infection of PAMs (p = 0.003; p = 0) (Figure 2.3E). The viral-titration assay to 
the culture media of treated PAMs further confirmed that the 10 µM Cpt treatment significantly 
blocked PRRSV infection/replication in PAMs (p = 0.001), resulting in about 2 log10 reduction 
of viral TCID50/mL titer compared to the control (Figure 2.3F). 
Cpt Pre- Plus Post-Treatment Inhibits the Infection of Several PRRSV Strains, and 
Cpt Post-infection Treatment Alone Also Inhibits PRRSV Infection of PAMs in vitro. To 
determine whether Cpt can also suppress the replication of other PRRSV strains within and 
across genotypes, Lelystad (LY) (type I strain) and SDSU73 (type II strain) PRRSV were used to 
infect PAMs. The PAMs were treated with Cpt for 24 h before inoculation and then for 21 h after 
virus inoculation. The cells were lysed and total RNAs were extracted to measure the PRRSV 
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infection of PAMs. qRT- PCR revealed that the replication of SDSU73 and LY strains were both 
inhibited by 5 µM or 10 µM Cpt (Figure 2.4A). Titration of the 21 h viral supernatants showed 
that 10 µM Cpt significantly suppressed the infection/replication of both SDSU73 and LY strains 
in PAMs (p = 0.002; p = 0), with more than 1 log reduction of viral TCID50/mL titer compared 
with the controls (Figure 2.4B). Taken together, our data demonstrated that Cpt treatment 
inhibited the infection/replication of 2 strains of type II PRRSV as well as Lelystad, the 
prototype strain of type I PRRSV in PAMs. We further questioned if the Cpt-treatment of PAMs 
after PRRSV inoculation (posttreatment alone) could also inhibit the viral infection. Cpt was 
supplemented at 5 or 10 µM to the culture media of PAMs after 1 h PRRSV VR-2332 
inoculation. We performed immunostaining at 24 h posttreatment and found that treatment with 
both 5 and 10 µM Cpt posttreatments significantly reduced the percentage of PRRSV-infected 
PAM cells at 24 h post-inoculation (Figures 2.4C, 2.4D). Total RNAs were also extracted at 21 h 
after Cpt treatment and the culture media from different conditions were collected. qRT-PCR 
revealed that post-inoculation treatment of PAMs with 5 or 10 µM Cpt significantly inhibited 
PRRSV infection of PAMs compared to the control (p = 0.007; p = 0.006), which was consistent 
with the suppressed CD163 expression in PAMs (Figure 2.4E). Viral titration of the culture 
media of treated PAMs further showed that 5 or 10 µM Cpt posttreatment after infection 
significantly reduced PRRSV titer in the culture media (p = 0.04) (Figure 2.4F). Treatment of 
PAMs with DMSO alone did not affect the outcome of PRRSV infection/replication in PAMs 
(Figure 2S.1). Thus, Cpt-treatment of PAMs after the PRRSV inoculation also inhibits the 
infection and replication of PRRSV in PAMs. 
Inflammatory Responses in PRRSV-infected PAMs to Cpt. Some inflammatory 
cytokines were measured in the 24 h pre-treated plus 21 h post-treated PRRSV-infected PAMs 
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(Figure 2.5). Compared to the uninfected PAMs, VR-2332 and Lelystad PRRSV elevated 
inflammatory IL-10 mRNA in the PAMs by 9-fold and 1.6-fold, respectively. The pro-
inflammatory IL-1β, IL-12p40, and IFNβ mRNAs in the PAMs were increased by at least 13-
fold, 41-fold, and 2000-fold upon infection by either VR-2332 or Lelystad infection. Cpt 
inhibited expression of these cytokines in the PRRSV-infected PAMs in a dose-dependent 
manner. In the VR-2332-infected PAMs, Cpt decreased IL-1β, IL-10, IL-12p40, and IFNβ 
mRNAs by at least 1-fold, 3-fold, 9-fold, and 4.5-fold, respectively compared to the infected but 
untreated PAMs. With regard to the Lelystad-infected PAMs, the Cpt inhibitory effect on 
cytokine mRNAs was less dramatic but demonstrated a similar pattern compared to Cpt effect on 
VR-2332-infected PAMs.  
2.4 Discussion 
PRRS is considered one of the most economically significant disease across world swine 
industry. Despite the fact that many MLVs or inactivated vaccines against PRRSV have been 
licensed in various regions depending on the circulating strains, and tremendous efforts to 
investigate more efficacious vaccines, vaccines that provide cross-protection against 
heterologous PRRSV strains are still lacking. Meanwhile alternative or adjunct methods to 
PRRSV vaccines are worthy of investigation to mitigate the adverse effects on the swine herd 
caused by PRRS. CD163, a type I scavenger receptor exclusively expressing on cells of 
monocyte-macrophage linage, has been well confirmed to be the key and universal receptor for 
diverse PRRSV strains (Burkard et al., 2017; Whitworth et al., 2015). Different approaches have 
been explored to block the expression of porcine CD163, including gene knockout, mRNA 
knockdown by microRNA, or stimulation of acute CD163 protein shedding by LPS and 
metalloproteinase (Calvert et al., 2007; Gao et al., 2013; Guo et al., 2014; Whitworth et al., 
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2015). Inhibiting CD163 expression in PAMs by targeting its regulatory signaling pathways with 
natural or synthetic compounds hold the potential to be a unique, practical, and economical 
approach to curtailing PRRS. In this research, we showed that CD163 expression was 
upregulated by IL-10 stimulated STAT3 in pig cells. Furthermore, we demonstrated that the 
natural compound and selective STAT3 inhibitor Cpt significantly inhibited CD163 expression 
in PAMs, the primary target of in vivo productive PRRSV infection. We further demonstrated 
that Cpt treatment of PAMs pre- or post-PRRSV inoculation could significantly inhibit type I 
and type II PRRSV infection. Previous studies show that CD163 mainly mediate PRRSV 
uncoating rather than viral internalization to the PAMs for productive infection (Van Gorp et al., 
2008, 2009; Vanderheijden et al., 2003). In our study, Cpt treatment post viral inoculation 
inhibited CD163 expression and therefore suppressed PRRSV replication in PAMs significantly, 
reconfirming that a crucial PRRSV replication step is blocked by targeting CD163. Future 
investigation into the exact viral replication step blocked by Cpt-treatment is warrantied. Our 
study identified a new potential approach to controlling PRRSV infection in pigs. 
Natural compounds selectively targeting certain signaling pathways have emerged as 
valuable resources to treat human diseases with increased efficacy and less cytotoxicity (Angulo 
et al., 2017; Ranjan et al., 2015; Wang et al., 2018b). Cpt is a natural compound derived from the 
Chinese herbal medicine Salvia miltiorrhiza (Danshen) (Chen et al., 2014; Shin et al., 2009). The 
safety of Cpt orally administered to rodents has been evaluated with no obvious adverse effects 
(Liu et al., 2015; Zhang et al., 2012), with significant effects against acute lung injury induced by 
lipopolysaccharide, improved symptoms of Alzheimer’s disease and atherosclerosis in various 
mouse models (Liu et al., 2015; Mei et al., 2009; Tang et al., 2014). Also, although CD163 
knockout pigs are PRRSV-resistant, potential long-term side effects on pig health and 
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development by the permanent deletion of CD163 gene still need to be evaluated. Inhibition of 
CD163 by modulating signaling pathway activity is reversible upon withdrawn of these 
compounds, providing a flexible alternative intervention to prevent PRRSV infection. It was 
recently reported that the CD163 abundance level on cell surface is pivotal for effective PRRSV 
infection (Wang et al., 2018a). This evidence is in line with the significance of this study that 
Cpt, a natural compound inhibits PRRSV infection by reducing the expression of CD163 in 
PAMs and may be readily applicable in vivo. It would be of interest to further screen other 
natural STAT3 inhibitors as well as to test the in vivo efficacy of Cpt to control PRRSV infection 
in pigs. 
In line with previous studies (Genini et al., 2008; Hou et al., 2012), Our study showed 
that infection by VR-2332 and Lelystad, the prototype strains of type I and type II PRRSV, 
respectively, both significantly increased IL-10 transcription in the PAMs. Meanwhile, Cpt 
drastically inhibited the PRRSV-infection-induced IL-10 transcription. IL-10 is a potent 
immunosuppressive cytokine that interacts with various immune cells, thus inhibiting innate and 
adaptive immunity, particularly the cell-mediated immune responses (Couper et al., 2008). IL-10 
induction in pigs following PRRSV infection is believed to be a focal mechanism that the 
PRRSV vaccine efficacy is compromised (Thanawongnuwech and Suradhat, 2010). 
Additionally, the pro-inflammatory cytokines in PAMs induced by PRRSV infection was 
substantially inhibited by Cpt treatment in this study, which is consistent with previous studies 
showing Cpt suppresses production of pro-inflammatory cytokines by inhibiting NF-κB 
signaling and MAPK signaling pathways (Maione et al., 2018; Tang et al., 2011). Altogether, 
these data suggest Cpt to be a potent immunoregulator in the PRRSV-infected pig cells. Future 
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investigation of Cpt’s potential to be a vaccine adjuvant in the control of PRRS is worthy of 
carrying out.  
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Table 2. 1 The sequences of primers for qRT-PCR in this study. 
                Primer group and namea.                                                            Sequence (5’ → 3’) 
























Figure 2. 1: IL-10 pathway regulates CD163 expression in PAMs. (A) qRT-PCR for PAMs 
treated with BSA (Ctl) or 100 ng/mL porcine IL-10 for 2 or 24 h. Values are normalized with 
GAPDH. Bars represent mean±sd of 3 independent experiments. PAMs of the 3 repeats were from 
one donor. P values were calculated using paired t-test. An asterisk indicates a comparison with 
the indicated control. *: p < 0.05. **: p < 0.01. PAMs of the 3 repeats were from one donor. (B) 
Immunostaining of PAMs treated for 24 h with BSA Ctl or 100 ng/mL IL-10. Bar = 120 µm. 
Inserted figures: Confocal images with overlay of DAPI (blue) and CD163 (red), or p-STAT3 








Figure 2. 2: Cpt inhibits IL-10 pathway activity and CD163 expression in PAMs. (A) Upper: 
Chemical structures of the 3 compounds. Lower: MTT assay of PAMs treated with the compounds 
for 24 h at various concentrations. Upper X-axis: percent concentration of DMSO. Lower X-axis: 
concentration of the compounds. Values represent mean±sd of 3 independent experiments. PAMs 
of the 3 repeats were from one donor. (B) qRT-PCR for SOCS3 expression in PAMs treated with 
various concentrations of small molecules with or without 100 ng/mL porcine IL-10 (Ctl) for 24 
h. Values are normalized with GAPDH. Bars represent mean±sd of 4 independent experiments. 
PAMs of the 4 repeats were from one donor. P values were calculated using Tukey’s post hoc 
comparison. An asterisk indicates a comparison with the indicated control. (C) qRT-PCR for 
CD163 expression in PAMs treated as described in B. Values are normalized with GAPDH. Bars 
represent mean±sd of 4 independent experiments. PAMs of the 4 repeats were from one donor. P 
values were calculated using Tukey’s post hoc comparison. An asterisk indicates a comparison 
with the indicated control. (D) WB (upper) and densitometry data (lower) for total proteins of 
PAMs stimulated with or without 100 ng/mL IL-10 for 24 h, and IL-10 with co-treatment of 20 
µM Cpt. Bars represent mean±sd of 4 independent experiments. PAMs of the 4 repeats were from 
4 donors.  (E) Immunostaining of PAMs treated for 24 h with BSA Ctl or 100 ng/mL IL-10, or IL-
10 plus 20 µM Cpt. Bar = 120 µm. Inserted figures: Confocal images with overlay of DAPI (blue) 
and CD163 (red). Bar = 8 µm. F. WB (upper) and densitometry data (lower) for total proteins of 
PAMs treated with DMSO Ctl or with 20 µM Cpt for 24 h. Bars represent mean±sd of 3 
independent experiments. PAMs of the 3 repeats were from 3 donors, P value was calculated using 







Figure 2. 3: Cpt pre- or pre- plus post-treatment inhibits PRRSV infection of PAMs. (A) 
qRT-PCR for CD163 and VR-2332 PRRSV expression in PAMs pre-treated with DMSO or Cpt 
for 48 h, and harvested at 21 h post PRRSV VR-2332 strain inoculation (MOI = 0.1). Controls 
were treated with 0.1% DMSO vehicle equivalent to what used by 10 µM Cpt. Values are 
normalized with GAPDH. Bars represent mean±sd of 3 independent experiments. PAMs of the 3 
repeats were from one donor. P values were calculated using Tukey’s post hoc comparison. An 
asterisk indicates a comparison with the indicated control. (B) TCID50 value for PRRSV titer in 
the culture supernatant of PAMs treated the same as described in A. Values represent mean±sd of 
3 independent experiments. PAMs of the 3 repeats were from one donor. P values were calculated 
using Tukey’s post hoc comparison. An asterisk indicates a comparison with the indicated control. 
(C) Representative images for PRRSV in PAMs after 24 h IL-10 and/or Cpt pretreatment and 
immunostained at 24 h post-inoculation. NC: non-infected DMSO treated negative control. PC: 
PRRSV VR-2332 strain infected positive control, DMSO treated. Inserted figures: Confocal 
images with overlay of DAPI (blue) and PRRSV (green). Bar = 8 µm. (D) The percentage of 
PRRSV positive PAMs treated as described in C. Values represent mean±sd of 3 independent 
experiments. PAMs of the 3 repeats were from one donor. (E) qRT-PCR for CD163 and PRRSV 
expression from PAMs pretreated for 24 h by DMSO or Cpt followed by 21 h posttreatment after 
PRRSV VR-2332 strain inoculation (MOI = 0.1). Values are normalized with GAPDH. Bars 
represent mean±sd of 3 independent experiments. PAMs of the 3 repeats were from one donor. P 
values were calculated using Tukey’s post hoc comparison. An asterisk indicates a comparison 
with the indicated control. (F) TCID50 value for VR-2332 PRRSV titer in the culture supernatant 
of PAMs treated the same as described in E. Values represent mean±sd of 3 independent 
experiments. PAMs of the 3 repeats were from one donor. P values were calculated using Tukey’s 
post hoc comparison. An asterisk indicates a comparison with the indicated control; *: p < 0.05; 






Figure 2. 4: Cpt pre- plus post-treatment inhibits the infection of several PRRSV strains, and 
Cpt-posttreatment alone also inhibits PRRSV infection of PAMs in vitro. (A) qRT-PCR for 
PRRSV expression from PAMs pretreated for 24 h with DMSO or Cpt followed by 21 h 
posttreatment after the PRRSV SDSU73 or LY strain inoculation (MOI = 0.1). Values are 
normalized with GAPDH. Bars represent mean±sd of 3 independent experiments. PAMs of the 3 
repeats were from one donor. P values were calculated using Tukey’s post hoc comparison. An 
asterisk indicates a comparison with the indicated control. (B) TCID50 value for PRRSV titer in 
the culture supernatant of PAMs treated the same as described in A. Values represent mean±sd of 
3 independent experiments. PAMs of the 3 repeats were from one donor. P values were calculated 
using Tukey’s post hoc comparison. An asterisk indicates a comparison with the indicated control. 
(C) Representative immunostaining pictures for PRRSV in PAMs after 24 h Cpt posttreatment 
after viral inoculation of PAMs. NC: non-infected, DMSO treated negative control. PC: PRRSV 
strain VR-2332 infected, DMSO treated. Inserted figures: Confocal images with overlay of DAPI 
(blue) and PRRSV (green). Bar = 8 µm. (D) The percentage of PRRSV VR-2332 positive PAMs 
treated the same as described in C. Values represent mean±sd of 3 independent experiments. PAMs 
of the 3 repeats were from one donor. P values were calculated using Tukey’s post hoc comparison. 
An asterisk indicates a comparison with the indicated control. (E) qRT-PCR for CD163 and 
PRRSV expression from PAMs treated for 21 h post PRRSV VR-2332 strain inoculation (MOI = 
0.1). Values are normalized with GAPDH. Bars represent mean±sd of 3 independent experiments. 
PAMs of the 3 repeats were from one donor. P values were calculated using Tukey’s post hoc 
comparison. An asterisk indicates a comparison with the indicated control. (F) TCID50 value for 
VR-2332 PRRSV titer in the culture supernatant of PAMs treated the same as described in E. 
Values represent mean±sd of 3 independent experiments. PAMs of the 3 repeats were from one 
donor. P values were calculated using Tukey’s post hoc comparison. An asterisk indicates a 





Figure 2. 5: Inflammatory response of PRRSV-infected PAMs to Cpt treatment. PAMs were 
pre-treated with DMSO or Cpt for 24 h and then incubated with or without PRRSV (VR-2332 or 
Lelystad) for 1 h (MOI = 0.1). The cells were further post-treated with DMSO or Cpt for 21 h. 
Total RNA was extracted from cells at 21 h post inoculation. Relative expression of IL-1β, IL-10, 
IL-12p40, and IFNβ mRNA were assessed using qRT-PCR. Values were normalized with GAPDH. 
Bars represent mean±sd of 3 independent experiments. PAMs of the 3 repeats were from one donor. 
P values between the uninfected group and virus group were calculated using paired t-test. P values 
between virus group and the two Cpt groups were calculated using Tukey’s post hoc comparison.  





























































































































































Figure 2S. 1: DMSO does not affect PRRSV infection in PAMs. TCID50 value for PRRSV titer 
in the culture supernatant of PAMs treated for 21 h post PRRSV strain VR-2332 inoculation (MOI 
= 0.1) with or without 0.1% DMSO (equivalent to the amount used in 10 µM Cpt). Values represent 
mean±sd of 3 independent experiments. PAMs of the 3 repeats were from one donor. P values 
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Abstract  Porcine reproductive and respiratory syndrome (PRRS) is an economically significant 
disease to the global pork industry and its causative agent is PRRS virus (PRRSV). Currently, 
vaccines, used to control this disease, can only confer effective protection against genetically 
homologous PRRSV strains, therefore, studies on alternative approaches to combatting this 
panzootic, are of great interest. Through an artificial intelligence molecular screen (AIMS) 
program, we obtained a set of small molecular compounds predicted to target the scavenger 
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receptor cysteine-rich domain 5 (SRCR5) of CD163, which is the key receptor for PRRSV 
infection. Using a cell-based bimolecular fluorescence complementation (BiFC) assay, we 
identified one synthetic compound (designated as B7) that significantly inhibits the protein-
protein interaction (PPI) between the PRRSV glycoprotein (GP2a or GP4) and CD163-SRCR5 
domain. We further demonstrated that compound B7 significantly inhibits PRRSV infection of 
porcine alveolar macrophages (PAMs) in vitro, the primary natural host cells of PRRSV in a 
dose-dependent manner. B7 exhibited similar efficacy in inhibiting the infection by multiple 
PRRSV strains in vitro. Further characterization of antiviral efficacy of B7 analogues identified 
several analogues which are also potent antiviral agents against PRRSV infection in vitro. 
Structural comparison among these compounds suggested that the 3-(morpholinosulfnyl)aniline 
moiety of B7 or the 3-(piperidinylsulfonyl)anilino moiety in a B7 analogue may be important for 
the inhibitory effect against PRRSV infection. Our study revealed a new approach to potentially 
preventing PRRSV infection in pigs by blocking the PRRSV-CD163 interaction using chemical 
compounds. 
Keywords  infection, SRCR5, PPI, PAMs, analogue 
3.1 Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is a panzootic infectious disease 
of pigs, causing major economic losses to the world-wide swine industry. The causative virus of 
PRRS (PRRSV) is an enveloped, positive-sense, single-stranded RNA virus belonging to 
Arteriviridae family, Nidovirales order (Benfield et al., 1992; Cavanagh, 1997). PRRSV 
infection may cause severe reproductive failure in sows and respiratory disorders in piglets 
(Wang et al., 2018). These syndromes are frequently accompanied by secondary infections with 
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even greater clinical manifestations and mortality for pigs of all age (Tian et al., 2007; 
Zimmerman et al., 1997). However, due to the high heterogeneity of PRRSV, broadly effective 
vaccines are lacking (Meng, 2000; Murtaugh et al., 2010; Nan et al., 2017). New approaches are 
needed to combat the PRRS panzootic to mitigate the devastating consequences of this disease. 
Productive PRRSV infection occurs primarily in porcine alveolar macrophages (PAMs) 
residing in the lungs (Murtaugh et al., 2002). CD163, a macrophage-specific membrane scavenge 
receptor, is a key receptor for PRRSV infection (Calvert et al., 2007; Delrue et al., 2010; Lee et 
al., 2010; Weingartl et al., 2002). The indispensability of CD163 expression for PRRSV 
infection was confirmed by knockout studies showing pigs lacking functional CD163 are 
resistant to PRRSV challenge (Wells et al., 2017; Whitworth et al., 2015). Out of the 9 
extracellular scavenger receptor cysteine-rich (SRCR) domains in CD163, the fifth SRCR 
domain (SRCR5) was found essential for PRRSV infection (Van Gorp et al., 2010) and 
monocytes/macrophages from pigs with a SRCR5 deletion of the CD163 gene show complete 
resistance to PRRSV infection (Burkard et al., 2017). Cellular pull-down assay revealed that 
minor glycoproteins GP2a and GP4 of PRRSV specifically interact with the CD163 molecule, 
and they bind the CD163 extracellular but not transmembrane or cytoplasmic region (Das et al., 
2010). Thus, it is reasonable to assume that the CD163-SRCR5 domain will directly interact with 
the PRRSV glycoproteins. However, assays studying protein-protein interactions (PPIs) between 
the CD163-SRCR5 domain and PRRSV glycoproteins have not been reported. A number of 
small molecules have been identified to effectively block the entry of various viruses infecting 
humans by binding and antagonizing the host cell receptors/co-receptors (Briz et al., 2006; 
Kaneko et al., 2018; Kaneko et al., 2015; Kuritzkes, 2009; Nkongolo et al., 2014; Qian et al., 
2009; Wang et al., 2015; Watashi et al., 2014). However, small molecules targeting the PPIs 
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between PRRSV and CD163 receptor have not been reported. A recent study on pig CD163 X-
ray crystal structure compared porcine CD163-SRCR5 domain with other members of the 
scavenger receptor cysteine-rich superfamily (M2BP and CD5) and revealed that the loop 5-6 
region within porcine CD163-SRCR5 domain may contribute to the receptor specificity of 
porcine CD163 for PRRSV infection (Ma et al., 2017). Furthermore, structure-based site-
directed mutagenesis elucidated a charged residue, the arginine residue at position 561 (Arg561) 
in the loop 5-6 region is important for PRRSV infection (Ma et al., 2017). This raises the 
possibility that targeting porcine CD163-SRCR5 domain with small molecules may prevent 
PRRSV infection. In this study, we established a BiFC assay to study the PPIs between PRRSV 
glycoproteins and the porcine CD163-SRCR5 domain. Using this assay, we were able to test a 
list of small molecules predicted to bind to the porcine CD163-SRCR5 domain and identify a 
compound that inhibits the PPIs between the PRRSV glycoproteins and SRCR5. We further 
characterize antiviral efficacy of this compound against PRRSV infection of PAMs. In addition, 
we validated the same efficacy of various analogues of this compound and revealed possible 
moieties that are important for inhibiting PRRSV infection. 
3.2 Materials and Methods 
Chemicals, Cells, and Viruses. All screening compounds were provided by Atomwise, 
Inc (CA, USA) or purchased from MolPort, Inc (NY, USA). Porcine alveolar macrophages 
(PAMs) were harvested from lungs of healthy 4–6-month old and PRRSV-negative 
Landrace/Yorkshire cross pigs. Lungs were transferred on ice to Biosafety Level 2 cabinet. 
Carefully injected warm PBS with 200 U/mL penicillin and 200 µg/mL streptomycin through the 
major trachea bronchi into both sides of the lungs. Lungs were massaged and the 
bronchoalveolar lavage fluid (BALF) was retrieved. The BALF was centrifuged at 400 g for 15 
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minutes to pelletize PAMs. The PAMs were then washed twice with warm complete medium. 
Cells were counted and frozen in 90% FBS (HI, Rocky Mountain Biologicals, Inc) and 10% 
DMSO (Sigma). Cells were stored in Mr. Frosty Freezing Container (Nalgene, USA), and put at 
-80 °C before being transferred to liquid nitrogen. PAMs were cultivated in RPMI-1640 (Gibco) 
supplemented with 10% FBS (HI, Rocky Mountain Biologicals, Inc), 2 mM Glutamax 
(Invitrogen), 0.1 mM MEM Non-Essential Amino Acids (Gibco), 1mM sodium pyruvate 
(Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco), and 0.5 µg/mL 
Amphotericin B (Gibco). All PRRSV strains were propagated and titrated in MARC-145 cells.  
AIMS Screen. Virtual screening was performed using AtomNet, the first deep neural 
network for structure-based drug design trained to predict protein-ligand binding 
affinity(Wallach et al., 2015). For targeting the interaction between the porcine CD163 and 
PRRSV glycoprotein (GP2a or GP4), the X-ray structure of CD163-SRCR5 domain 
(PDBID:5HRJ) was used to define a screening site centered around R561 comprising residues 
C502, S503, D505, W540, A541, E543, A559, P560, R561, P562, D563, G564, and C566 
(Figure 3S.2). The Mcule library of commercially available organic small molecule compounds 
(~4M v20171018) was prepared and screened, as described previously(Hsieh et al., 2019), using 
an ensemble of protein-ligand conformations. Each of the 4M molecules was scored and ranked 
by AtomNet, following which a top set of 200 chemically diverse compounds was further 
inspected for undesirable substructures and molecular properties before 74 compounds were 
obtained for experimental testing. 
Plasmid Construction. N terminus and C terminus of the truncated Venus-I152L were 
inserted into vector backbone pMyc-CMV and pCMV-HA, constituting commercial plasmids 
pBiFC- VN155(I152L) and pBiFC-VC155, respectively (Addgene, Watertown, MA, USA) 
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(Kodama, Y. et al., Biotechniques, 2010). cDNA fragments for the scavenger receptor cysteine-
rich domain 2 (SRCR2) and SRCR5 of porcine CD163 receptor, and for VR-2332 PRRSV 
glycoproteins GP2a and GP4 were amplified by RT-PCR. The amplified cDNA fragments of 
SRCR2 or SRCR5 were sub-cloned into the pBiFC-VN155(I152L) vector digested with 
EcoRI/BglⅡ. For constructions of GP2a and GP4 fusion proteins, cDNA fragments encoding 
GP2a or GP4 were sub-cloned into the pBiFC-VC155 vector digested with EcoRI/BglⅡ. All 
plasmid clones were verified by DNA Sanger sequencing. 
BiFC Assay. HEK293T cells cultured in 12-well plates were transfected with appropriate 
plasmids for each BiFC assay using FuGENE® 6 (Promega, Madison, WI, USA). After 4 h, 
various concentrations of chemical compounds were added to the culture media. DMSO was 
used as the vehicle control. Fluorescence images of treated cells at 24 h after plasmid 
transfection were captured using an inverted Nikon fluorescence microscope. Fluorescence 
intensity of treated cells was measured by ImageJ (https://imagej.nih.gov/ij/).   
Cytotoxicity Assay. The cytotoxicity of selected screening compounds was determined 
in PAMs, the principal host of productive PRRSV infection. Briefly, various concentrations of 
the compounds were added to PAMs seeded in 24-well plates and incubated for 24 h. Then 50 µl 
of the 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) labeling reagent (In 
Vitro Toxicology Assay Kit, MTT based, Sigma-Aldrich) were added to each well and incubated 
for 4 h before 500 µl of the solubilization solution was added into each well to fully dissolve the 
formazan crystal by overnight incubation. The absorbance of samples was measured using a 
spectrophotometry microplate reader at 600 nm. PAMs treated with DMSO served as controls. 
Quantitative Reverse Transcription – PCR (qRT-PCR). For relative quantification of 
PRRSV in PAMs, total RNA was extracted from PAMs infected with PRRSV using RNeasy 
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Mini Kit (Qiagen, Germantown, MD) according to the manufacturer’s instruction. RNA 
concentrations were measured using a Nanodrop spectrophotometer (Thermo Fisher Scientific). 
Specific real time qPCR primers for the ORF7 gene of the four PRRSV strains and for porcine 
GAPDH are shown in Table 3.2. GAPDH was used as the housekeeping gene for gene 
expression normalization. Data were processed with the software associated with ABI 7500. 
Western Blotting. Whole cell proteins were isolated from HEK293T cells. Briefly, the 
cells were rinsed twice with cold PBS. After removing the PBS, cold RIPA buffer 
(ThermoFisher Scientific) supplemented with 1% (v/v) protease and phosphatase inhibitors was 
added to the cells and placed on ice for 5 min. Protein concentrations were determined using 
Pierce BCA Protein Assay Kit (ThermoFisher Scientific). Equal amount of denatured proteins 
from each sample were separated on 10% SDS-PAGE and transferred onto a PVDF membrane. 
The membrane was incubated with 5% skim milk to block nonspecific binding before incubation 
with Myc-Tag mouse monoclonal antibody (1:1000, Cell Signaling Technology, Danvers, MA) 
or anti-GAPDH antibody (1:1,000; Cell Signaling Technology, Danvers, MA) overnight at 4 °C. 
After washing with 1× T-BST, the membrane was incubated with HRP-conjugated secondary 
antibody (Cell Signaling Technology, Danvers, MA) for 1 h at room temperature, and image 
developed with ECL Blotting Substrates (Bio-Rad) and visualized under the ChemiDox XRS 
Image System (Bio-Rad). 
PRRSV Infection and Titration Assay. For PRRSV infection of PAM cells, PAMs 
were seeded one day prior to infection. The cells were treated with DMSO as the control or with 
the selected screening compounds (5-20 µM) for 4 h before inoculation, and for 24 h after 
inoculation. Cells were inoculated with VR-2332, SDSU73, NADC30 or Lelystad PRRSV (MOI 
= 0.1) for 1 h. The 24 h cell medium supernatant was stored at -80 °C until future titration assay.  
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For PRRSV titration assay, MARC145 cells were seeded in 48-well plates and grew to 
~80% confluency density before inoculation. Viral supernatants were prepared by 10-fold serial 
dilution, and 100 µl of the dilutions was added per well in six replicates. Inoculum was removed 
from cells after 2 h and replaced with 0.5 mL of DMEM supplemented with 2% FBS, 2 mM 
Glutamax, 0.1 mM MEM Non-Essential Amino Acids, and 50 U/mL penicillin and 50 µg/mL 
streptomycin (Invitrogen) to each well. Cells were cultured at 37 °C for 6 days and then the 
cytopathic effects were recorded. The PRRSV titer was calculated using the Reid and Müench 
method and expressed as median tissue culture infectious dose (TCID50/mL). 
Statistical Analysis. All experiments were performed at least 3 times. Data were 
analyzed by one-way ANOVA with Tukey’s post hoc comparison or by paired t-test. Data were 
expressed as mean ± sd and p < 0.05 was considered to be significant. 
3.3 Results 
Establishment of BiFC Assays to Identify Small Molecules That Inhibit the PPI 
between PRRSV and CD163. Using the previously described BiFC vector (Kodama and Hu, 
2010) based on the N terminus (VN155(I152L), hereafter named VN) and C terminus (VC-155, 
hereafter named VC) of the fragmented Venus-I152L, we established fusion protein constructs 
between the porcine CD163 protein SRCR5 or SRCR2 domain and VN, and between the 
PRRSV minor glycoprotein (GP2a or GP4) and VC (Figures 3.1A, 3S.1). We co-expressed these 
plasmids in HEK293T cells to evaluate the PPIs between the SRCR5 domain and GP2a (or 
GP4). In agreement with the validated critical role of CD163-SRCR5 in mediating the PRRSV 
infection (Burkard et al., 2017; Van Gorp et al., 2010), the CD163-SRCR5/VN fusion protein 
(SRCR5-VN) interacts with GP2a/VC and GP4/VC fusion protein, with strong fluorescence 
detected under the microscope (Figures 3.1B, 3.1C, top panel). In contrast, the fusion protein of 
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CD163-SRCR2 domain (SRCR2-VN), which is dispensable for the PRRSV infection and 
PRRSV-CD163 interaction (Van Gorp et al., 2010), only showed background fluorescence when 
co-expressed with GP2a/VC or GP4/VC fusion protein (Figures 3.1B, 3.1C, lower panel). These 
data indicate that the porcine CD163-SRCR5 domain interacts directly with PRRSV 
glycoproteins GP2a and GP4. 
We then asked whether the BiFC assays we established could be used to identify small 
molecules with potential to block the interaction between CD163 and PRRSV. A structure-based 
virtual screening program named artificial intelligence molecular screen (AIMS) performed by 
Atomwise, Inc. (San Francisco, CA) was used to screen 4 million compounds within a small 
molecule library for affinity to the previously published 3-D protein structure of porcine CD163-
SRCR5 domain (Ma et al., 2017). A list of 74 small molecules were predicted most likely to bind 
ensemble porcine CD163-SRCR5 domain by Atomwise, Inc. (San Francisco, CA). In the cellular 
assays, we tested these compounds using our BiFC assay, to evaluate their potential of inhibiting 
the PPI between GP2a and SRCR5. SRCR5-VN and GP2a/VC plasmids were co-transfected in 
HEK293T cells. Four hours after the two plasmids were added, the screened small molecules 
were administered individually to cells at 5 µM. At 24 h, fluorescence from reconstituted Venus-
I152L was captured under a fluorescence microscope and fluorescence intensity was quantified. 
Of all the 74 small molecules, we identified an active compound designated herein as B7 (4-
Fluoro-2-methyl-N-[3-(3-morpholin-4-ylsulfonylanilino)quinoxalin-2-yl]benzenesulfonamide, 
C25H24FN5O5S2, Figure 3.1D) that significantly inhibited the fluorescence in our assay (Figure 
3.1E). We further verified that B7 also inhibited the PPI between PRRSV GP4 and SRCR5 using 
the other BiFC assay (Figure 3.1F). 
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Validation of the Function of Compound B7 to Inhibit the PRRSV Infection of 
PAMs. Based on the demonstrated inhibitory effect of B7 compound on the interaction between 
CD163-SRCR5 domain and PRRSV glycoproteins, we then asked whether this compound will 
inhibit the PRRSV infection of PAMs. MTT assay at 24 h revealed that B7 compound is well 
tolerated by PAMs at concentrations below 25 µM, with the lethal concentration, 50% (LC50) 
calculated (Finney, 1952) at 81.7 µM (Figure 3S.3). Primary PAMs were then pre-treated with 
B7 ranging from 0 – 20 µM for 4 h, followed by 1 h inoculation with PRRSV strain VR-2332 
(MOI = 0.1). The infected PAMs were then continuously incubated with B7 compound at 
various concentrations. At 24 h post inoculation (24hpi), total RNAs were extracted from PAMs. 
Quantitative reverse transcription – PCR (qRT-PCR) revealed a dose-dependent inhibition of 
PRRSV infection of PAMs by the B7 treatments (Figure 3.2A). Viral titration further confirmed 
that B7 compound at concentrations between 10 µM and 20 µM reduced viral load in the 24hpi 
supernatant substantially, with 2-3 log10 reduction in titer at 15 µM and 20 µM (p = 0; p = 0) 
(Figure 3.2B). 15 µM and 20 µM B7 treatments exerted similar anti-PRRSV activity. 15 µM was 
chosen for later assays considering to minimize compound cytotoxicity. 
The antiviral effect of B7 compound was further tested on heterologous PRRSV strains. 
PAMs were pre-treated with DMSO as the control or 15 µM B7 for 4 h, and inoculated with 
PRRSV strains VR-2332, SDSU73, NADC30 (Type II) or Lelystad (Type I) for 1 h (MOI = 
0.1), and continuously incubated with DMSO or 15 µM B7 for 24 h. qRT-PCR revealed that B7 
significantly inhibited infection of PAMs for all the 4 PRRSV strains (p = 0.004; p = 0.008; p = 
0.003; p = 0.001) (Figure 3.2C). This viral inhibitory effect is further confirmed by viral titration 
assay showing that for all of the 4 strains, viral loads in 24hpi cell culture supernatant of the 
infected PAMs were decreased by more than 2 log10 infectious units by 15µM B7 (p = 0.005; p = 
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0.002; p = 0.003; p = 0.008) (Figure 3.2D). Thus, B7 compound provides PAMs with cross-
protection against type I and type II PRRSV in vitro. 
Evaluating Anti-PRRSV Activity of Small Molecules with Similar Chemical 
Structure to B7 compound. B7 is a synthetic compound with its biological activities 
undocumented previously. In order to examine the structural relevance of B7 molecule to the 
PRRSV inhibition, we performed PubChem search for similar compounds and obtained an 
additional 6 compounds structurally related to B7 (designated herein as B7-A1 to B7-A6, Figure 
3.3A, Table 3.1). We first used our BiFC assay as described above to test if any of these B7 
analogues can inhibit the PPI between CD163-SRCR5 domain and PRRSV GP2a protein. 
Similar as B7 (p = 0), compounds B7-A1 to B7-A4 all significantly inhibited the PPI between 
CD163-SRCR5 and PRRSV GP2a in our BiFC assay (p = 0; p = 0; p = 0.001; p = 0) (Figures 
3.3B, 3.3C). Interestingly, shifting the 3-(morpholinosulfonyl)anilino moiety of B7 to 4-
(morpholinosulfonyl)anilino position (B7-A2), or to 3-(piperidinylsulfonyl)anilino moiety (B7-
A4, blue circle) does not eliminate the compound activity of inhibiting the PPI between CD163-
SRCR5 and PRRSV GP2a (Figures 3.3B, 3.3C). However, replacing the 3-
(piperidinylsulfonyl)anilino or 3-(morpholinosulfonyl)anilino moiety with morpholine in 
compounds B7-A5 and B7-A6 (Figure 3.3A, red circle) completely blocked their ability of 
inhibiting the PPI between CD163-SRCR5 and PRRSV GP2a (Figures 3.3B, 3.3C).  
We further asked whether these active small molecules in the BiFC assay inhibit PRRSV 
infection of PAMs. MTT assay at 24 h revealed that these small molecules have no obvious 
cytotoxic effect on PAMs at 15 µM (Figure 3S.4). PAMs were then pre-treated with these active 
small molecules (B7-A1 to B7-A4) or B7-A5 (as a reference) at 15 µM individually for 4 h and 
inoculated with PRRSV strain VR-2332 for 1 h (MOI=0.1). The cells were then continuously 
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incubated with 15 µM of the same small molecules. Total RNAs were extracted from infected 
PAMs at 24 hpi, and qRT-PCR revealed that similar as B7 (p = 0), these active small molecules 
in the BiFC assay (B7-A1 to B7-A4) all inhibited the PRRSV RNA level in the treated PAMs (p 
= 0.039; p = 0.022; p = 0.048; p = 0.01) (Figure 3.3D) compared with the control. Treatment 
with B7-A5, however, failed to inhibit PRRSV RNA level in the infected PAMs (Figure 3.3D). 
Titration of progeny PRRSV in the 24 hpi cell culture supernatant of infected cells further 
confirmed that compounds B7-A1 through B7-A4 but not B7-A5 inhibited PRRSV infection of 
PAMs (p = 0; p = 0; p = 0; p = 0; p = 0.965) (Figure 3.3E). We also speculated that the 3-
(morpholinosulfonyl)anilino moiety (in B7 and B7-A1 through B7-A3) and the 3-
(piperidinylsulfonyl)anilino moiety (in B7-A4) could be pharmacophores important for the anti-
PRRSV activity.  
3-(morpholinosulfonyl)anilino or 3-(piperidinylsulfonyl)anilino Alone in A Small 
Molecule Does Not Inhibit PRRSV Infection. We also noticed that removing the methyl and/or 
fluoro groups from the benzenesulfonamide moiety of B7 (compound B7-A3) weakened the 
compound inhibitory activity in our BiFC assay (Figures 3.3B, 3.3C) and PRRSV infection assay 
(Figures 3.3D, 3.3E), though the difference is not as dramatic as modifying the 3-
(morpholinosulfonyl)anilino moiety. In order to determine if the 3-(morpholinosulfonyl)anilino 
or 3-(piperidinylsulfonyl)anilino moiety alone in a small molecule is sufficient to suppress the 
PRRSV infection, we purchased 2 compounds with either of these 2 moieties as the only 
chemical constituent. We designated them as B7-A7 and B7-A8, respectively (Figure 3.4A). We 
pre-treated PAMs with 15 µM of each molecule for 4 h prior to 1 h VR-2332 PRRSV inoculation 
(MOI=0.1). The cells were then further post-treated with either compound for 24 h. Titration of 
progeny PRRSV in the 24 hpi cell culture supernatant of the treated cells revealed that neither of 
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these 2 compounds inhibited PRRSV infection of PAMs (Figure 3.4B). Therefore, while these 2 
moieties are functionally critical for B7 and its analogues, the presence and modification of other 
chemical structures (e.g., benzenesulfonamide) could also be important for the inhibition of 
PRRSV infection.  
B7 Compound Has Its Anti-PRRSV Activity Exclusively during Post-inoculation 
Period. We have validated the inhibitory effect of B7 on PRRSV infection upon pre- and post-
inoculation treatments. We further asked whether treatment with B7 either pre- or post-
inoculation will have any significant effect on PRRSV infection. PAMs were either treated with 
15 µM B7 for 4 h followed by PRRSV strain VR-2332 inoculation (MOI=0.1) with no post-
treatment, or treated with 15 µM B7 for 24 h post PRRSV-inoculation (MOI=0.1) without pre-
treatment. At 24 hpi, we evaluated viral RNA in PAMs and the PRRSV titer in cell culture 
supernatant. qRT-PCR showed that B7 post-treatment alone exhibited comparatively inhibitory 
effect on PRRSV infection to the pre- plus post-treatment (Figure 3.5A). This finding was further 
supported by titration of progeny PRRSV in the 24hpi cell culture supernatant (Figure 3.5B). 
However, the inhibitory effect of B7 on PRRSV infection was very negligible if incubated with 
cell only prior to inoculation (Figures 3.5A, 3.5B). This led us to speculate B7 did not exert 
inhibitory effect on PRRSV infection prior to PRRSV inoculation, the B7 binding to the cells are 
weak and reversible, and that its inhibitory effect is transient upon withdrawal of B7 compound. 
We further treated PAMs with DMSO as the Ctrl or 15 µM B7 for 4 h prior to VR-2332 
or Lelystad PRRSV inoculation for 1h (MOI=0.1). RNA was extracted from the PAMs 
immediately after the inoculation and the level of cell-bound viral RNA was relatively quantified 
by RT-qPCR. These data suggested B7 pretreatment did not inhibit viral binding to the PAMs 
(Figure 3.5C). To this end, we asked whether the lack of inhibitory effect of B7 pretreatment on 
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viral binding was due to the absence of B7 during the 1h PRRSV inoculation (Figures, 3.5A, 
3.5B). PAMs were then inoculated with VR-2332 PRRSV (MOI = 0.1) for 1 h during which the 
cells were also treated with DMSO as the Ctrl or 15 µM B7. After the inoculation, the cells were 
immediately subject to RNA extraction (0 hpi), or incubated without any treatment for 24 h 
before RNA extraction (24 hpi). The viral RNAs at 0 hpi and 24 hpi were relatively quantified by 
RT-qPCR. The results indicated viral binding to the PAMs were not significantly inhibited even 
if the PAMs were consistently exposed to B7 compound during the inoculation (Figure 3.5D). 
Figure 3S.5 further suggested B7 treatment did not significantly affect PRRSV infectivity during 
the 1 h inoculation, ruling out the possibility that infectivity lost might interfere in the viral 
binding. Altogether, B7 compound has its anti-PRRSV activity exclusively during the post-
inoculation period. 
3.4 Discussion 
Although the porcine CD163-SRCR5 domain has been identified to be critical for 
PRRSV infection (Burkard et al., 2017; Van Gorp et al., 2010) and PRRSV glycoproteins GP2a 
and GP4 have been validated to specifically interact with porcine CD163 receptor (Das et al., 
2010), no study has been performed to validate whether porcine CD163-SRCR5 domain directly 
interacts with PRRSV glycoproteins during the infection. Using BiFC assay, we demonstrated 
that the CD163-SRCR5 domain can interact directly with PRRSV glycoprotein GP2a and GP4. 
We further identified a small molecule designated as B7 which can block the interaction between 
CD163-SRCR5 domain and PRRSV GP2a/GP4, consequently inhibiting the infection of PAMs 
by type I and type II PRRSV in vitro. In addition, we identified several active B7 analogues with 
anti-PRRSV activity. The high consistency of the infection assay data with the BiFC assay 
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results suggested our BiFC assay to be reliable tool for preliminarily screening small molecules 
for anti-PRRSV activity. 
We found that B7 post-inoculation treatment inhibited PRRSV infection to a similar 
degree as the B7 pre- plus post-inoculation treatment, while the B7 pre-inoculation treatment had 
negligible anti-PRRSV effect (Figures 3.5 A, 3.5B). This suggests a reversible association of B7 
compound with porcine CD163-SRCR5 domain: upon the removal of B7 compound, the 
inhibition in the interactions between PRRSV glycoproteins and porcine CD163-SRCR5 domain 
could be lifted. Further structure activity relationship (SAR) analysis has yet to be performed to 
predict the docking site of B7 compound in porcine CD163-SRCR5 domain. We further verified 
that B7 treatment does not inhibit virion binding (Figures 3.5.C, 3.5.D left) and internalization 
(Figure 3.4.D right) to PAMs in vitro, suggesting that B7 compound does not target some 
reported viral attachment factors, such as heparan sulphate and sialoadhesin (Delputte et al., 
2005). Our finding that treatment with B7 has its anti-PRRSV activity exclusively during the 
post-inoculation period is consistent with the reported activity of porcine CD163 receptor in 
PRRSV infection. Porcine CD163 receptor interacts with PRRSV GP2a and GP4 proteins and 
mediates viral uncoating, which occur prior to virion binding and internalization to the host cells 
(Van Gorp et al., 2008). 
Despite tremendous efforts, no vaccines currently available are effective against 
heterologous PRRSV strains. Developing alternative prevention approaches to vaccines are of 
great interest. The inhibition of key PPIs between PRRSV and CD163 with natural or synthetic 
compounds is a unique and promising approach to controlling the PRRS panzootic. B7 
compound, screened by our BiFC assay, has not been documented previously in terms of its 
biological activities. The finding that compound B7 as well as some of its derivatives 
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substantially decrease PRRSV infection of PAMs in vitro (2-3 log10 infectious units) makes them 
promising agents worthy of further investigation of their anti-PRRSV activity in pigs. 
Additionally, Our study indicates that the inhibitory function of B7 and its analogues may 
depends on the intact 3-(morpholinosulfonyl)anilino or the 3-(piperidinylsulfonyl)anilino moiety, 
which provides further clues for developing more potent compounds against PRRSV infection 
and minimizing the side effects of these compounds. This finding, combined with a full 
understanding of the key residues in CD163-SRCR5 domain involved in PRRSV recognition, 
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Figure 3. 1: Establishing BiFC assays and screening compounds that can inhibit the PPI 
between PRRSV and CD163. (A) Schematic Diagram for the BiFC Assay Fusion Protein 
Constructs between Pig CD163 SRCRs or PRRSV Minor Envelope Glycoproteins and the 
Fragments of Venus Protein VN155(I152L) or VC155), Respectively. (B) Left: SRCR5-VN or 
SRCR2-VN plasmids were co-transfected with GP2a-VC to HEK293T cells, with fluorescent 
images taken at 24 h after transfection. Bar = 250 µm. Right: Cell fluorescence quantified by 
ImageJ. Mean±SD. n=3. P values were calculated using paired t-test. An asterisk indicates a 
comparison with the indicated control. **: p < 0.01. (C) Left: SRCR5-VN or SRCR2-VN plasmids 
were co-transfected with GP4-VC to HEK293T cells, with fluorescent images taken at 24 h after 
transfection. Bar = 250 µm. Right: Relative fluorescence intensity quantified. Mean±SD. n=3. P 
values were calculated using paired t-test. An asterisk indicates a comparison with the indicated 
control. **: p < 0.01. (D) Chemical structure of compound B7. (E) Left: BiFC assay between 
SRCR5-VN and GP2a-VC proteins. Images showing positive inhibitory effect of compound B7 
but not B8, with DMSO as the Ctrl. Bar = 250 µm; Right: Relative fluorescence intensity quantified. 
Mean±SD, n=3. Means by the uncommon letter in each column are significantly different (p<0.05). 
(F) Left: BiFC assay between SRCR5-VN and GP4-VC proteins showing similar inhibitory effect 
by B7 compound but not by B8. Bar = 120 µm. Right: Relative fluorescence intensity quantified. 






Figure 3. 2: Inhibition of PRRSV infection to PAMs by B7. (A) qRT-PCR for PRRSV in total 
RNAs extracted from PRRSV strain VR-2332 infected PAMs treated with various concentrations 
of B7 compound. Values are normalized with GAPDH of PAMs. Bars = mean±SD, n=3. PAMs 
of the 3 repeats were from 3 donors. P values were calculated using Tukey’s post hoc comparison. 
An asterisk indicates a comparison with the indicated control.  ***: p < 0.001. (B) Titration assay 
results for PRRSV in the culture media of PAMs treated as described in (A). Bars = mean±SD, 
n=3.  (C) qRT-PCR for PRRSV in total RNAs extracted from PAMs infected by different strains 
of PRRSV and treated with 15 µM of B7 compound. Values are normalized with GAPDH of 
PAMs. Bars = mean±SD, n=3. PAMs of the 3 repeats were from 1 donor. P values were calculated 
using Tukey’s post hoc comparison. An asterisk indicates a comparison with the indicated control. 
**: p < 0.01. (D) Titration assay results for PRRSV in the culture media of PAMs treated as 






Figure 3. 3: Evaluating the PRRSV inhibitory effect for compounds structurally similar to 
B7. (A) Molecular structures of B7 analogues (B7-A1 to A6) compared with B7. (B) BiFC assay 
between SRCR5-VN and GP2a-VC proteins. Representative fluorescent images showing different 
effects of compound B7 and its analogues on the PPI of SRCR5/GP2a, with DMSO as the Ctrl. 
Bar = 250 µm. (C) Relative fluorescence intensity in (B) quantified by ImageJ. Mean±SD, n=3. P 
values were calculated using Tukey’s post hoc comparison. An asterisk indicates a comparison 
with the indicated control. **: p < 0.01, ***: p < 0.001. (D) qRT-PCR for PRRSV in total RNAs 
extracted from PRRSV strain VR-2332 infected PAMs treated with 15 µM of B7 and its analogues. 
Values are normalized with GAPDH of PAMs. Bars = mean±SD, n=3. PAMs of the 3 repeats were 
from 1 donor. P values were calculated using Tukey’s post hoc comparison. An asterisk indicates 
a comparison with the indicated control. ***: p < 0.001. (E) Titration assay results for PRRSV in 








Figure 3. 4: 3-(morpholinosulfonyl)anilino or 3-(piperidinylsulfonyl)anilino alone does not 
inhibit PRRSV infection. (A) Molecular structures of B7-A7 and B7-A8. (B) Titration assay 
results for the culture media of PAMs treated with B7, B7-A7, or B7-A8 and infected by PRRSV 
strain V-2332. Bars = mean±SD, n=3. PAMs of the 3 repeats were from 1 donor. P values were 
calculated using Tukey’s post hoc comparison. An asterisk indicates a comparison with the 





Figure 3.4: 3-(morpholinosulfonyl)anilino or 3-(piperidinylsulfonyl)anilino Does Not 
Inhibit PRRSV Infection and Post-Treatment with B7 Alone Inhibits PRRSV Infection. (A) 
Molecular structures of B7-A7 and B7-A8. (B) Titration assay results for the culture media of 
PAMs treated with B7, B7-A7, or B7-A8 and infected by PRRSV strain V-2332. Bars = 
mean±SD, n=3. ***: P < 0.001. (C) qRT-PCR for PRRSV in total RNAs extracted from PAMs 
infected by PRRSV VR-2332 and treated with 15 µM of B7 compound at pre and/or post-
inoculation. Values are normalized with GAPDH of PAMs. Bars = mean±SD, n=3. *: P < 0.05. 
(D) Titration assay results for PRRSV in the culture media of PAMs treated as described in (C). 
















Figure 3. 5: B7 compound has its anti-PRRSV activity exclusively during post-inoculation 
period. (A) qRT-PCR for PRRSV in total RNAs extracted from PAMs infected by PRRSV VR-
2332 and treated with 15 µM of B7 compound at pre and/or post-inoculation. Values are 
normalized with GAPDH of PAMs. Bars = mean±SD, n=3. PAMs of the 3 repeats were from 3 
donors. P values were calculated using Tukey’s post hoc comparison. An asterisk indicates a 
comparison with the indicated control. *: p < 0.05. (B) Titration assay results for PRRSV in the 
24hpi cell culture supernatant of PAMs treated as described in (A). Bars = mean±SD, n=3. ***: p 
< 0.001. (C) The PAMs were pre-treated with DMSO as the Ctrl or 15 µM B7 for 4 h. Subsequently, 
the cells were inoculated with VR-2332 or Lelystad PRRSV for 1h (MOI = 0.1) and were not post-
treated before RNA was extracted from PAMs for RT-qPCR. Bars = mean±SD, n=3. PAMs of the 
3 repeats were from 3 donors. P values were calculated using 1-sample t-test (D) The PAMs were 
inoculated with VR-2332 PRRSV (MOI = 0.1) for 1 h. During the 1 h inoculation, the cells were 
also treated with DMSO as the Ctrl or 15 µM B7. Subsequently, the cells were frozen for RNA 
extraction, or incubated without treatment for 24 h before RNA extraction. Bars represent mean±sd 
of 3 independent experiments. PAMs of the 3 repeats were from 1 donor. P values were calculated 


















































































































Figure 3S. 1: Western blotting of the BiFC SRCR5-VN, SRCR2-VN, and vector VN proteins. 
 
 

















Figure 3S. 3: MTT assay of the B7 compound incubated with PAMs for 24 h. scatter plots = 




Figure 3S. 4: MTT assay of B7 analogue compounds incubated with PAMs at 15 µM for 24 h. 





















































Figure 3S. 5: B7 treatment does not affect PRRSV infectivity. VR-2332 and Lelystad, the two 
prototype strains of type II and type I PRRSV, respectively, were incubated with DMSO as the 
Ctrl or 15 µM B7 at 37°C for 1h. Then the viruses were directly used for virus titration. Since at 
the endpoint of 50% of the cells were infected, the B7 had been diluted to extremely low 
concentration alongside the viruses, the possible effect of B7 on PRRSV entry to the cells was 
negligible. Therefore, the titration results appropriately represented PRRSV infectivity. Bars 























Table 3. 1: B7 and B7 analogue compounds screened. 
Designated 
ID Structure Name 
B7 
 
























































































Table 3. 2: The sequences of primers used in this study. 















Chapter 4. Conclusion and Prospectus  
PRRS is known to be one of the most economically significant disease across global 
swine industry. Current MLVs only provide swine herd with efficient protection against 
homogeneous PRRSV strains, but not genetically divergent strains. In this dissertation, we 
identified some small molecules that inhibit PRRSV infection of PAMs in vitro, the primary 
target of productive infection, by heterologous PRRSV strains. These screened chemical 
compounds are alternative agents other than MLVs to potentially combat the PRRS panzootic. 
In chapter 2, we demonstrated that interleukin 10 (IL-10) stimulated JAK/STAT3 
signaling serves as a central signaling regulating expression of scavenger receptor CD163 in 
PAMs. Out of 3 STAT3 inhibitors well documented in humans, we identified cryptotanshinone 
(Cpt), a natural compound extracted from the herb Salvia miltiorrhiza (Danshen), was least 
cytotoxic to PAMs and significantly downregulated IL-10-stimulated and basal level of CD163 
expression. Subsequently, we characterized Cpt’s anti-PRRSV activity and showed that it was 
able to efficiently inhibit PRRSV infection of PAMs by type I and type II PRRSV strains in 
vitro. Some of the questions related to Cpt’s anti-PRRSV activity and worthy to be investigated 
are listed below. 1) Considering Cpt is least cytotoxic to PAMs, would some antiviral effects still 
be observed when the assay time is prolonged? 2) Furthermore, considering its potent effect on 
immune modulation, it would be interesting to investigate the effect of Cpt on phenotypic change 
of T lymphocytes and thus on cell-mediated immune responses in vitro: incubate PRRSV-
infected monocyte-derived dendritic cells with or without Cpt treatment, and then co-culture 
these infected cells with lymphocytes for a certain period (lymphocytes can be retrieved from 
 
 103 
supernatant of PBMC cell culture since they are non-adherent); then percentages of Foxp3+ 
CD25+ T lymphocytes is measured by flow cytometry; activity of T regulatory cells induced by 
PRRSV-infected dendritic cells is evaluated by determining the proliferation of PHA-stimulated 
PBMC co-cultured with lymphocytes previously co-cultured with PRRSV-infected dendritic 
cells. 
In chapter 3, a list of compounds was predicted most likely to bind porcine CD163-
SRCR5 domain by a structure-based virtual screen program named artificial intelligence 
molecular screen (AIMS). We further screened these compounds in cellular assays using an 
established cell-based BiFC assay. We identified one active small molecule (4-Fluoro-2-methyl-
N-[3-(3-morpholin-4-ylsulfonylanilino)quinoxalin-2-yl]benzenesulfonamide, C25H24FN5O5S2), 
designated herein as B7, substantially disrupted PPI between PRRSV glycoproteins and CD163-
SRCR5 domain. We further found the disrupted PPI by B7 compound could lead to block of VR-
2332 PRRSV infection of PAMs, and that B7 compound protected PAMs against type I and type 
II PRRSV strains in vitro. Later, we demonstrated some B7 analogues inhibited infection of 
PAMs by VR-2332 PRRSV whereas the other analogues had no antiviral efficacy. By comparing 
the chemical structures of these small molecules and linking their structural differences to their 
antiviral performances, we proposed either 3-(morpholinosulfonyl)anilino moiety in B7 
compound or the 3-(piperidinylsulfonyl)anilino moiety in a B7 analogue could be 
pharmacophore important for controlling PRRSV infection. However, some questions are still 
worthy of investigation in the future. 1) Perform structure activity relationship (SAR) analysis to 
predict binding site of these active small molecules in the porcine CD163-SRCR5. 2) Conduct 
ligand-based virtual screening for the proposed pharmacophores and obtain additional small 
molecules for cellular assays. This could make identification of additional anti-PRRSV small 
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molecules possible. 3) After all the cellular assays, we will have obtained quite a few active 
small molecules with anti-PRRSV activity in vitro, it would then be interesting to pick a lead 
compound for characterization of anti-PRRSV activity in pigs. First, investigate the compound 
safety by scoring the lesions of different organs such as lungs, liver, kidney, and spleen of pigs 
with compound injection. Then based on the compound half-life in pigs, dose pigs with the lead 
compound repeatedly and intramuscularly prior to or post challenge with VR-2332, NADC30, 
SDSD73 or Lelystad PRRSV via both intranasal and intramuscular routes. Measure the viral 
loads in the serum of different days post inoculation and in the end post mortem examinations 
are performed. Lung lesion scoring is done by people blinded to the treatment groups. Viral 
loads in the lung lobe, tracheobronchial lymph nodes, spleen, and inguinal lymph nodes are 
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